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These guidelines are intended for use by all health 
care practitioners working with pregnant women 
experiencing a drug or alcohol use problem, particularly
drug dependency, but including other drug uses such 
as bingeing.
Those practitioners include (but are not limited
to) general practitioners, midwives, obstetricians,
paediatricians, nurses, early childhood workers, lactation
consultants, dieticians, social workers, drug and alcohol 
specialist doctors, drug and alcohol workers, Aboriginal
health workers, accident and emergency staff, 
psychologists, psychiatrists and mental health workers. 
Child protection workers and probation and parole 
officers will also find the guidelines helpful.
Who should use these guidelines?
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The adverse effects on fetal development of alcohol 
and other drugs such as tobacco, psychostimulants and 
opioids are well known. Women who are pregnant 
or who may become pregnant are therefore a high
priority for interventions to reduce drug use. There has, 
however, up to now been limited information to guide
clinicians in the care of these women and infants.
These nationally agreed clinical guidelines are intended
to support a range of health care workers who care 
for pregnant women with drug and alcohol use issues,
and their infants and families. The guidelines are based 
on the best currently available evidence, developed 
through a rigorous process in which international and 
Australian research literature was reviewed by experts 
and consensus achieved.
Substances discussed in these guidelines include the 
licit substances alcohol and tobacco; illicit substances 
opioids, amphetamines, cocaine, cannabis and 
inhalants; and prescription medication known for its
misuse, benzodiazepines. Other topics covered include
breastfeeding, vertical transmission of blood-borne 
viruses, obstetric implications, pain management during
labour, psychosocial issues, the management of neonatal 
abstinence syndrome and early childhood development. 
In addition, where relevant, specific guideline statements 
identifying the needs and care of Aboriginal and Torres 
Strait Islander women with drug and alcohol use issues
are also included.
The evidence reviews on these topics have been 
published as a monograph ‘Background Papers to 
the National Clinical Guidelines for the Management 
of Drug Use during Pregnancy, Birth and the Early 
Development Years of the Newborn’ and are also 
available through the National Drug Strategy website
www.nationaldrugstrategy.gov.au/publications/index.htm
and through the NSW Health website
www.health.nsw.gov.au/ These papers provide both 
detailed analyses of the available evidence and extensive
reference lists that are not included with the guidelines.
This book is organised in four sections. The first
describes some general principles of management and 
care. The second focuses on the progression of the 
pregnancy, so that care is described in the antenatal, 
birthing and postnatal periods, as well as the early 
childhood years. The third section is organised according
to each drug group, while the fourth attends to the care 
of the neonate.
The guidelines emphasise the importance of establishing
a sound therapeutic relationship with the woman based 
on respect and non-judgmental attitudes; of engaging
the woman into adequate antenatal care through this
relationship; and of maintaining continuity of care, 
and of carers, throughout the pregnancy and 
postnatal period.
The guidelines recommend that pregnant women with
significant problematic drug or alcohol use will benefit
from appropriate referral for specialist drug and alcohol 
assessment (in addition to midwifery and obstetric
care); appointment of a consistent and continuous
case manager and care team who use effective
communication systems; and specific treatments 
for their drug use, which may include counselling,
pharmacotherapies and relapse prevention strategies.
Introduction
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The quality of scientific evidence supporting these guidelines is indicated throughout by quoting a ‘level of evidence’
for each statement. 
I Evidence obtained from a systematic review of all relevant randomised controlled trials.
II Evidence obtained from at least one properly designed randomised controlled trial.
III-1 Evidence obtained from well-designed pseudo randomised controlled trials (alternate allocation
or some other method).
III-2 Evidence obtained from comparative studies (including systematic reviews of such studies) with
concurrent controls and allocation not randomised (cohort studies), case control studies, or 
interrupted time series with a control group.
III-3 Evidence obtained from comparative studies with historical control, two or more single arm 
studies, or interrupted time series without parallel control group.
IV Evidence obtained from case series, either post-test or pre-test and post-test.
CONSENSUS In the absence of scientific evidence and where the executive committee, steering committee
and workshop group are in agreement, the term ‘consensus’ has been applied.
CONSENSUS IN 
[REFERENCE]
Evidence obtained from a published extensive review of the literature that is not a systematic
review or meta analysis.
This definition of levels of evidence is adapted from: 
National Health and Medical Research Council of Australia. A guide to the development, implementation and evaluation
of clinical practice guidelines. Canberra: NH&MRC, 1999. www.nhmrc.gov.au/publications/synopses/cp65syn.htm
The 1999 levels of evidence were developed primarily to describe evidence gathered from intervention studies and did
not include the level ‘Consensus’, which was added in 2003 in the document ‘Evidence-based management of acute 
musculoskeletal pain’ (2003, p. 184) www.nhmrc.gov.au/publications/synopses/cp94syn.htm.
The level ‘Consensus in [reference]’ was added in these guidelines, and is only used in the section on tobacco.
Where the evidence is based on a systematic review, a meta analysis or other extensive review, a citation has been 
included after the level of evidence. Otherwise, no citations have been included.
Levels of evidence
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The adverse effects on fetal development of alcohol 
and other drugs such as tobacco, psychostimulants
and opioids are well known. Women who are pregnant 
or who may become pregnant are therefore a high
priority for interventions to reduce drug use. It is also 
possible that women may be more prepared to change 
drug using behaviour if they are pregnant or may 
become pregnant, which can improve the success 
of appropriate interventions.
Prevention programs should target all women of 
child-bearing age, including those still at school. 
All women need to know the risks associated with
drug use. 
In assessing a young, pregnant woman, where episodic
binge use or regular drug use may be an issue, it is
important to consider the woman’s social supports 
and emotional well-being as well as drug use.
Information about drug use and its effects may be 
provided by a range of services, including general 
practitioners, women’s health providers, maternity
services, Aboriginal health services, public health 
information services or schools.
Level of evidence: Consensus
1General principles
1.1  Drug use information for all women of child bearing age
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These guidelines are intended for use by all health 
care practitioners working with pregnant women who 
have a drug or alcohol use problem, particularly drug 
dependency, but including other drug uses such 
as bingeing.
The guidelines recommend that pregnant women with
problematic drug or alcohol use will benefit from:
? appropriate referral to specialist assessment and help, 
such as a drug and alcohol specialist, in addition to 
midwifery and obstetric care
? appointment of a case manager and care team who 
remain consistent throughout the pregnancy
? specific treatments for their drug use, which
may include counselling, pharmacotherapies and 
relapse prevention.
1.2.1 Contraception
Exposure to drugs and alcohol may have a serious
effect on the fetus in the very early stages of pregnancy, 
particularly before the first missed period. Therefore, all 
women with problematic drug or alcohol use should be 
provided with advice on contraception. This will facilitate
planned rather than unplanned pregnancies, and reduce 
harm to the unborn child.
1.2.2 Vertical transmission of blood-borne viruses
Before pregnancy it is important that all drug-dependent 
women of child-bearing age receive information about 
vertical transmission of blood-borne viruses, specifically:
? preventing transmission
? management after infection
? implications for pregnancy
? implications for breastfeeding.
1.2.3 Mental health issues
Mental health in women who use drugs or alcohol is
important at all stages of pregnancy. The two most 
important responses from health care workers are to:
? recognise signs of mental illness (particularly
psychosis, suicide risk, risk of harm to fetus or baby, 
postnatal depression) and
? refer appropriately to specialist services.
See section 2.2.9, Coexisting mental health and drug 
and alcohol use issues.
1.2.4 Confidentiality
Confidentiality is a fundamental right of all people 
using health care services. In all communications it is
important to work within the privacy legislation and 
local guidelines to ensure privacy and confidentiality are 
maintained. In regard to people who use drugs or who 
have infectious diseases (especially blood-borne viruses),
confidentiality takes on a particular significance because 
of the social stigma attached to these conditions.
1.2.5 Pregnancy care facilities
Pregnancy care facilities should have information
about which services have the capacity to support 
their staff by secondary consultation, mentoring and 
training. Professionals with the requisite knowledge and 
supervised experience in this work may include social
workers, psychologists, drug and alcohol clinicians and 
counsellors, Aboriginal health workers, child protection
workers, medical staff, nurses and midwives who work 
in specialist maternity units of drug treatment services.
The contact details of specialist support services should 
be readily available for pregnancy care providers,
including after hours contact details, especially where 
multidisciplinary pregnancy care is not available. Refer 
to section 2.2.12, Multi-agency collaboration.
1.2.6 Child protection
All State and Territory jurisdictions have specific
legislation with regard to child protection. Although 
drug and alcohol use alone may not be an indicator for 
a child protection report or notification, child protection
is a consideration in all drug and alcohol interventions
for pregnant women. Legislation requires that the 
safety and well-being of the child is a paramount 
consideration. Refer to section 2.2.20, Child
protection issues.
1.2  Care of all drug-dependent women of child bearing age
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Continuity of care for drug-dependent 
pregnant women
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Continuity of care and of carers is now accepted in
Australia as best practice for all pregnant women. All 
pregnancy care providers and maternity services should 
be aiming to provide continuity of care for all pregnant 
women, regardless of their background. Multidisciplinary
teams working collaboratively can achieve optimal
pregnancy, birth and parenting outcomes for each 
woman and her family. A multidisciplinary team can 
include midwife, obstetrician, neonatologist, community
health care worker, Aboriginal health worker, drug and 
alcohol counsellor and others as required in each case.
The case manager, midwife or team should ensure that 
continuity of care is maintained into the postnatal period
regardless of the venue for providing this care. 
Continuity of care, and of caregivers, takes on added 
importance for vulnerable groups, such as women 
with drug and alcohol use issues. Continuity of care is
established by: 
? effective engagement skills, including cultural 
awareness skills
?? an effective system which clearly identifies the 
main case worker/case manager
?? individualised care planning made in consultation
with the woman
? timely and accurate documentation and 
communication
?? a seamless referral system.
Level of evidence: Consensus
Comment: Pregnant women with drug and alcohol use 
issues do not always engage easily with mainstream 
health care. Continuity of care and of carers during and 
after pregnancy will assist in ensuring adequate care. 
This will minimise the number of women and infants 
being lost to follow up within complex health services.
Aboriginal and Torres Strait Islander women
Effective partnerships between mainstream services and 
Aboriginal Community Controlled Health Services must 
be developed to improve communication, integrate
service delivery and provide continuity of care.
Level of evidence: Consensus
It is recommended that clinical interventions with
Aboriginal and Torres Strait Islander pregnant women be 
guided by the six common principles identified by the 
Ministerial Council on Drugs Strategy (2003–2006) for 
addressing substance use by Aboriginal and Torres Strait
Islander peoples. These are:
? The use of alcohol, tobacco and other drugs must 
be addressed as part of a comprehensive, holistic
approach to health that includes physical, spiritual,
cultural, emotional and social wellbeing, community
development and capacity building.
? Local planning is required to develop responses to 
needs and priorities set by local Aboriginal and Torres 
Strait Islander communities.
? Culturally valid strategies that are effective for 
Aboriginal and Torres Strait Islander peoples must be 
developed, implemented and evaluated.
? Aboriginal and Torres Strait Islander peoples must 
be centrally involved in planning and implementing
strategies to address use of alcohol, tobacco and 
other drugs in their communities.
? Aboriginal and Torres Strait Islander communities
should have control over their health, drug and 
alcohol and related services.
? Resources to address use of alcohol, tobacco and 
other drugs must be available at the level needed to 
reduce disproportionate levels of drug-related harm 
among Aboriginal and Torres Strait Islander peoples. 
(Ministerial Council on Drugs Strategy 2003–2006)
Level of evidence: Consensus
2.1 Continuity of care and of carers
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2.2.1 Engagement 
The first antenatal presentation, wherever and whenever 
that may occur (including in Accident and Emergency 
after hours, or presenting for the first time in labour), 
is an opportunity to engage the pregnant woman and 
her family in pregnancy care that will ideally continue
through the birth to postnatal and early childhood care.
Level of evidence: Consensus
Comment: Drug-dependent pregnant women, like other 
vulnerable populations, may be difficult to engage and 
maintain in pregnancy care. Each presentation of a drug-
dependent pregnant woman to a health care service, 
including after hours presentations, is an opportunity to 
engage the woman effectively in care.
The aim of engagement is to establish a professional,
trusting and empathetic relationship in which the 
woman will feel encouraged to continue pregnancy 
care. Successful engagement may rest on the quality
of the relationship established with the woman by the 
health care providers she meets. 
Level of evidence: Consensus
Comment: The aim of this relationship is for the woman 
to feel safe, to build trust in the health care providers, 
and to empower her to seek what is best for her health 
and the health of her unborn baby. 
The maxim to ‘inform and advise about risks’ may 
not be a sufficient intervention for a drug-dependent 
pregnant woman. The quality of the relationship
between the woman and the health care provider is
a very significant factor in maintaining the woman 
in care. While information must still be provided, a 
‘partnership model’ is considered more appropriate in
the relationship between a drug-dependent pregnant 
woman and her health care providers.
Level of evidence: Consensus
Engagement is a prerequisite to care being provided.
Failure of engagement may result in loss of that woman 
to follow-up, with less than optimal outcomes for the 
woman and infant. Engagement of vulnerable groups 
into care requires specific skills and experience of 
clinicians. All clinicians need training in the specific skills
required to engage vulnerable groups in care. 
Level of evidence: Consensus
2.2.2 Engagement skills 
Engagement skills include:
? An understanding of one’s own values and beliefs in
a way that results in non-judgemental attitudes to 
people in care.
? An awareness that drug and alcohol use is not 
isolated from other psychosocial and cultural factors.
? Commitment to providing optimal and timely health 
care for every individual.
? An understanding of addiction as a health care 
issue and not an issue for moral, social or other 
judgements.
? An ability to create an environment that is safe and 
ensures privacy and confidentiality.
? An understanding of potential barriers to the 
woman accepting pregnancy care, and strategies
for overcoming them. 
? Acknowledgement of the woman’s feelings
 and perceptions.
? An understanding that disclosing drug and alcohol 
use in pregnancy is difficult.
? An understanding of the significance of establishing
and sustaining a sound and trusting professional
relationship with women with drug and alcohol issues. 
? Awareness that women with drug and alcohol issues
often have a number of service providers involved in
their lives.
2.2.3 Aboriginal and Torres Strait 
Islander women
Priority should be given to providing Aboriginal and 
Torres Strait Islander cultural awareness training to 
all maternal and child health care providers and drug 
and alcohol service providers. This is fundamental to 
the delivery of respectful and effective health care 
and should address the impact of colonisation and 
dispossession on the health status of Aboriginal and 
Torres Strait Islander people. 
Level of evidence: Consensus
Comment: Cultural sensitivity and awareness are key 
skills of engagement, particularly when engaging 
Aboriginal and Torres Strait Islander Peoples in care. 
Training is required to develop these skills in the health 
care workforce.
2.2 Antenatal care
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2.2.4 Literacy
Health care workers need to be aware that low literacy
reduces access to health information and this in turn 
affects people’s ability to practise a healthy lifestyle.
Many (although by no means all) women with drug 
or alcohol use issues have other social disadvantages,
and this may include low literacy. Therefore all 
information should be provided verbally as well as 
in writing, and discussed with the woman (and her 
partner) to ensure understanding.
Level of evidence: Consensus
Women from culturally and linguistically diverse (CALD) 
backgrounds are not necessarily literate in their first
language. The extent to which a woman received school 
education may depend on the country of origin and 
the age at which she emigrated. Therefore it is not 
enough to provide information brochures in the spoken 
language. A professional health care interpreter should 
also be used.
Level of evidence: Consensus
2.2.5 Screening 
General screening for drug and alcohol use 
Screening for drug and alcohol use should be included
in the usual antenatal history. All pregnant women 
should be asked for their current and previous history
of drug and alcohol use at initial assessment (time of 
confirmation of pregnancy, at first booking-in visit, or 
first presentation), to help decide the appropriate model 
of pregnancy care or provider. This screening should be 
repeated at periodic re-assessment. Simple questions
about what drugs have been used from the time of 
conception (or earlier if possible) are appropriate for 
screening. Ask specifically about:
? prescribed medications (including opioid
replacement therapies)
? over the counter medications eg paracetamol
? alcohol
? tobacco
? other substance use (this may include cannabis,
stimulants (speed, ecstasy, cocaine), opioids,
inhalants and unprescribed use of benzodiazepines).
It is important to establish the pattern and frequency 
of use, determining whether each substance is used 
occasionally, on a regular recreational or non-dependent 
basis or whether there is habitual, regular or dependent 
use. From a child protection perspective, regular, daily
or near daily use and binge use are of most concern 
(see section 2.2.20, Child protection issues). It is also 
important to establish whether there are patterns of 
concurrent or serial use of different substances. In this
interaction with the woman, clinicians should avoid
expressions that may be interpreted as judgemental, 
such as ‘addict’, as these may undermine the trust and 
openness crucial to obtaining an accurate history and for 
retaining the woman in continuing care. 
Level of evidence: Consensus
Comment: The information provided about drug and 
alcohol use as much as three months before conception 
provides insight in regards to the maternal drug 
use at conception, and is particularly relevant in the 
development of fetal alcohol syndrome. 
Information about most prescribed medications may 
be obtained from designated agencies in each State 
or Territory (see Appendix 2: Advice for consumers on 
drugs, alcohol and medications 
Screening for alcohol
All pregnant women should be asked about their level 
of alcohol consumption. If women are drinking over the 
recommended NH&MRC levels during pregnancy, then 
a full assessment of alcohol intake should be undertaken 
and appropriate referrals should be made. A validated
screening tool such as T-ACE, TWEAK or AUDIT should 
be used.
Level of evidence: Consensus
Comment: Incorporating a validated alcohol screening 
tool into antenatal assessment is likely to substantially 
increase the detection rate of women using excessive 
amounts of alcohol. No specific screening tool is 
recommended, but if one is used, it should be a 
validated and reliable tool. T-ACE and TWEAK are 
validated and reliable tools that have been developed 
for use with pregnant women. However, they may 
not be useful with lower levels of drinking that may 
still be risky in pregnancy (as defined in the Australian 
Alcohol Guidelines). AUDIT is a validated tool, but is 
not designed specifically for use during pregnancy. The 
relationship established between the pregnant woman 
and the health care worker may influence the woman’s 
willingness to disclose alcohol use and hence health care 
workers should seek this information in a sensitive and 
empathetic manner.
Screening for tobacco
The first step in treating tobacco use and dependence is
to identify tobacco users and recent quitters. Identifying
smokers itself increases rates of clinical intervention.
Effective identification of smoking status guides clinicians 
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to identify appropriate interventions based on the 
individual’s current tobacco use and willingness to quit.
Level of evidence: Consensus in Fiore et al 2000
All pregnant women should be asked at their first
antenatal assessment about smoking status to identify
those who need further support to stop smoking.
Level of evidence: I (Cochrane review: Lumley et al 2001) 
Comment: Smoking during pregnancy carries a social 
stigma, and clinicians must bear this in mind when 
asking pregnant women about smoking. Effective 
engagement skills and sensitive questioning by the 
health care worker are believed to facilitate accurate 
disclosure by pregnant women.
There is strong evidence that written questionnaires that 
provide the opportunity for multiple-choice responses to 
the question about smoking status, rather than simple
yes/no options, including the options ‘I used to smoke’ 
and ‘I have cut down’, are more likely to provoke 
accurate disclosure of smoking status. 
Level of evidence: II (Melvin et al 1994)
Screening for inhalants 
Routine screening for inhalant use is recommended 
for all pregnant women identified as being at risk of 
inhalant use. Risk level varies between urban, rural and 
remote communities. Health care workers undertaking
antenatal screening must be aware of the risk level in
their local community, and screen accordingly. 
Level of evidence: Consensus
Urine drug screening for illicit drugs
Pregnant women should have urine drug screens no 
less often than other women in similar circumstances 
(eg when in an opioid treatment program).
Level of evidence: Consensus
Comment: The efficacy of urine drug testing for 
pregnant women in unclear. There is some evidence that 
within a trusting professional relationship, self-disclosure 
of drug use may be reliable.
Screening for blood-borne viruses
It is cost effective to screen all drug-dependent 
pregnant women for blood-borne viral infections early 
in pregnancy, particularly where evidence supports the 
benefits of interventions to reduce the risk of vertical
transmission to the newborn.
Level of evidence: Consensus
All screening for blood-borne viruses must be conducted 
with the informed consent of the woman, and with
appropriate pre-test and post-test counselling.
Level of evidence: Consensus
Screening for human immunodeficiency virus (HIV)
It is cost effective to screen for HIV infections, even in
a low prevalence population such as Australia’s.
Level of evidence: III-3
Screening for hepatitis C virus (HCV)
Routine testing for blood-borne viruses including HCV 
is recommended for all pregnant women identified as 
having been at risk of transmission. The main risk factor 
is a history of injecting drug use, even when this has 
been infrequent or a long time in the past. Other risk
factors include being born or raised in countries with
high prevalence of HCV, blood transfusion before 1990, 
tattooing, and occupational exposure.
Level of evidence: IV
Comment: HCV may be transmitted from mother to 
baby during childbirth. No strategies have yet been 
shown to reduce this risk. The risk is increased by HIV 
co-infection, although HIV antiretroviral therapy can 
mitigate this effect. At the present time, HCV cannot be 
treated during pregnancy. Accordingly, the benefits of 
identifying this infection during pregnancy are indirect. 
Pregnancy is a point of contact with the health care 
system, during which women receive blood tests and 
medical review. If an HCV antibody test is positive, 
further investigation is required to determine viral status 
(eg HCV PCR test). Liver function tests should also 
be conducted.
Screening for hepatitis B virus (HBV)
Irrespective of drug history, all pregnant women should 
be tested for hepatitis B surface antigen. Passive
immunisation of the infant is particularly effective in
reducing the risk of vertical transmission.
Level of evidence: Consensus
Clinical considerations
Liver disease and cirrhosis place severe stress on mother 
and baby. Regardless of viral hepatitis status, patients
with clinically evident liver disease should be referred to 
an appropriate liver specialist or centre for management.
Level of evidence: Consensus
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2.2.6 Comprehensive drug use assessment 
and treatment planning
If there is a history of drug use, referral to a skilled
provider may be required for a comprehensive
assessment to:
? Ascertain whether the woman is or may be drug 
dependent.
? Inform the woman of the known risks in pregnancy 
of the particular drug(s) used, emphasising the 
potential for harm.
? Inform the woman about her options for specialist
care, drug and alcohol counselling and treatment 
options. Initiate referrals according to her decision.
Level of evidence: Consensus
Comment: If it is possible and will not compromise 
engagement, these issues can be discussed at the first 
presentation. If it is not possible at that visit — for 
example, if the woman is intoxicated or distressed by 
symptoms of withdrawal — a full assessment of drug 
use must be undertaken early in the pregnancy, over 
the next one or two visits. Clinicians will use their skills 
and experience in making decisions about the most 
appropriate timing for gathering this information. 
See Appendix 3: Examples of drug use assessment tool.
2.2.7 Partner/support person
From the first visit the partner (or support person and 
family if relevant) will be included in all stages of care, 
including discussions about drug use, provided that the 
woman’s informed consent has been obtained before 
any discussions in front of others. Informed consent 
requires full disclosure of what will be discussed
with others.
Level of evidence: Consensus
Comment: It is appropriate to offer interventions to the 
woman’s partner if that person has problematic drug or 
alcohol use. A partner’s drug use increases the woman’s 
risk of continuing or relapsing to drug use.
2.2.8 Psychosocial assessment
Planning for discharge should commence at the first
antenatal visit. Psychosocial assessment for discharge
planning should consider:
? financial issues and poverty 
? inadequate or inappropriate housing
(or homelessness) 
? domestic and intimate partner violence
? sexual abuse and assault
? relationship issues
? legal issues
? previous history of child protection issues
? a history of mental illness.
The woman must be supported to address psychosocial
issues that may affect outcomes of the pregnancy or 
result in an avoidable separation of mother and baby 
due to child protection requirements. Support needs 
are likely to vary according to the stage of pregnancy 
or parenting and may include material assistance,
practical support, emotional support and support to 
establish non-drug using networks, as well as drug use 
interventions. Counselling and other support should be 
initiated early in pregnancy.
Level of evidence: Consensus
2.2.9 Coexisting mental health and drug 
and alcohol use issues
All health care workers involved in pregnancy care must 
be able to recognise signs of serious mental health 
problems, specifically:
? anxiety and depression
? psychosis (including delusions and hallucinations)
? suicidal or self-harming ideation or planning
? unsafe ideas, plans or behaviour towards the fetus, 
infant or other person.
In such cases, the health care worker must
? Refer urgently to a specialist psychiatric service
for assessment and advice (for example, a liaison
psychiatry team).
? Where urgent referral is not an available option
(such as in remote areas), seek expert advice from 
a specialist psychiatric service. Such services are 
available in each State and Territory by telephone.
? Ensure that the woman is safe while awaiting
consultation. This may include a staff member 
remaining with the woman to ensure her safety and 
the safety of the fetus or infant.
Health care services should ensure that these procedures 
are familiar to all clinicians working with pregnant women.
Level of evidence: Consensus 
Comment: Ongoing care of a woman with mental 
health problems requires consultation with her mental 
health case worker, or other clinician as available, and a 
plan for the birth and after the birth. It may require drug 
information be included in the woman’s medical chart 
(especially for women who are on antipsychotic, mood 
stabilising or antidepressant medications). Symptoms of 
mental health problems may not be obvious without a 
mental health assessment or questioning, in which not 
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all midwives may be skilled. (This is an area suitable for 
workforce development.)
2.2.10 Ongoing assessment and treatment 
planning at each visit
As the pregnancy progresses, the following issues must 
be reviewed at each appointment:
? compliance with care and counselling
? maternal and fetal wellbeing
? drug, alcohol and tobacco use
? drug, alcohol and tobacco use of partner and others 
in the same house
? socioeconomic circumstances and psychosocial issues
(poverty, homelessness, domestic violence)
? mental health
? (if relevant:) withdrawal symptoms and dose of 
pharmacotherapy.
Level of evidence: Consensus
Comment: The quality of antenatal care may 
significantly affect neonatal outcomes. Refer to Part 4, 
Management of neonatal abstinence syndrome (NAS). 
2.2.11 Multidisciplinary team 
A skilled multidisciplinary team is ideal to provide
care for the drug-dependent pregnant woman. Such 
a team consists of specialists and generalists relevant 
to each woman’s situation. These might include (but 
are not limited to) a general practitioner, midwife,
obstetrician, social worker, drug and alcohol specialist
doctor, psychologist, psychiatrist, mental health worker, 
drug and alcohol worker, dietician, Aboriginal health 
worker, paediatrician, early childhood worker, lactation
consultant, or probation and parole officer. Where 
such multidisciplinary care is not available, women with
complex drug and alcohol use issues will require transfer 
to a centre able to provide such care or liaison with a 
specialist under a shared care arrangement.
Level of evidence: Consensus
Aboriginal and Torres Strait Islander women
In both urban and remote areas, Aboriginal health 
workers, Aboriginal liaison officers and Aboriginal health 
education officers are integral members of the primary
health care team providing clinical care, health education
and liaison services between Aboriginal women, hospital
services and community-based services.
Level of evidence: Consensus
2.2.12 Multi-agency collaboration
In some circumstances, a collaborative response from 
more than one agency may be of benefit to mother 
and family. The multi-agency response may include
drug and alcohol services, family support services,
child protection services, Aboriginal medical services,
general practitioners, probation and parole services,
and community welfare organisations.
Level of evidence: Consensus
Comment: Such an approach requires coordination 
which can be undertaken by the case manager.
Aboriginal and Torres Strait Islander women
Wherever possible, Aboriginal and Torres Strait Islander 
pregnant women with drug dependencies should be 
referred to an Aboriginal Medical Service (AMS), or 
a primary health care service which provides culturally 
appropriate care. This will assist in ensuring that 
multidisciplinary care is provided before, during and 
after pregnancy, and during the early childhood
years. Where women choose care or require care in
a maternity service or tertiary centre, shared care 
should be considered, with referral to an Aboriginal
support worker.
Level of evidence: Consensus
2.2.13 Allocating case manager or care 
coordinator 
To ensure continuity of care and adequate risk
management, a case manager should be appointed to 
oversee the woman’s care and liaise with other members 
of her care team. There must be absolute clarity about 
who is the primary case manager. It must be clear to 
the woman, to the rest of the team, and to the case 
manager. The woman must be provided with contact 
details for the case manager and care team. Refer to 
section 2.2.15, Communication.
Level of evidence: Consensus
Comment: Without a definite case manager, continuity 
and consistency of care is difficult to achieve. Variations 
occur in different State and Territory jurisdictions with 
regard to the discipline of the case manager, who may 
be a midwife, nurse, general practitioner, Aboriginal 
health worker, psychologist, social worker, or private 
obstetrician. Variations also occur in how the case 
manager is allocated. The case manager should be 
proactive in the care of the woman, for example, 
following her up assertively (but respectfully) if she does 
not attend appointments. The case manager participates 
in regular team meetings and case conferences and 
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provides a formal hand-over to those caring for the 
woman and infant during the birth and postnatal 
period. If the woman is in an opioid treatment program, 
there should be close liaison with the pharmacotherapy 
prescriber and/or dosing point. 
2.2.14 Written care plan
A plan of care will be formulated in conjunction with
the woman (and partner or support person if relevant). 
The plan should be written and readily available to other 
health workers (such as in the case notes), particularly
if the woman presents out of hours. The plan must be 
reviewed regularly with mother, who should have a copy. 
Level of evidence: Consensus
Comment: The woman must be involved in formulating 
and reviewing the plan for it to be meaningful to her, 
and for her to be committed to participate in it.
2.2.15 Communication 
Pregnant women who engage in risky drug or alcohol 
use may access pregnancy care only intermittently. 
To support the woman to remain in care, systematic
communication strategies and protocols should be 
established between members of the pregnancy care 
team. The woman and all the team members need 
to know each person’s role and contact details. The 
case manager will play a key role in keeping everyone 
informed (see section 2.2.13, Allocating case manager 
or care coordinator).
Level of evidence: Consensus
Comment: Regular case conferences are an example of 
a systematic communication strategy.
2.2.16 Preparation for discharge
Discharge planning with the woman and her identified
support people must begin at the first antenatal 
presentation. Involving the woman and the family in
the care plan will facilitate progress in the postnatal 
period. The potential need for postnatal residential care 
for some mothers and babies should be considered and 
planned before the birth as residential care places may 
be in short supply.
Level of evidence: Consensus
Comment: Some pregnant drug-dependent women may 
have immediate issues or a chaotic lifestyle that make 
discharge planning seem irrelevant. In these situations 
the priority must be to help such women stabilise their 
lives to enable planning for the future.
2.2.17 Preparation for the birth and the 
postnatal period
Preparing for the birth and the postnatal period
will include the usual antenatal preparations and 
childbirth education, with particular consideration
of the following issues:
Birth
? options for pain relief, particularly for opioid-
dependent women (see section 2.3, Labour 
and birth)
? timing and mode of birth, taking account of the 
risk indicators present, such as presence of HIV 
(see section 2.6, Vertical transmission of blood-
borne viruses)
? advisability of presenting early in labour to 
minimise the need for self medication and 
to monitor drug use.
Postnatal period 
? choices for infant feeding
? risks and benefits of breastfeeding, taking into
account drug and alcohol use, medications, and the 
presence of blood-borne viruses (refer to section 2.5, 
Breastfeeding)
? neonatal abstinence syndrome and treatment options
(particularly for the opioid-dependent mother)
? possibility of extended hospital stay for the infant
and mother
? safe sleeping practices and risk factors for sudden 
infant death
? the effects of environmental tobacco smoke (refer 
to section 3.2.9, Environmental tobacco smoke and 
section 2.5, Breastfeeding)
? parenting education, and the option of participating
in classes tailored for drug-dependent women 
? issues around the safety of the home environment, 
particularly with regard to safe storage of any 
medications kept in the home, including methadone 
take away doses.
Level of evidence: Consensus
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2.2.18 Late presentations
Women who present for the first time in the third 
trimester, or in labour, have a high risk of pregnancy 
complications as a result of inadequate antenatal care. 
Although each individual’s situation is unique, and may 
not include drug or alcohol use, if possible the preferred 
management is:
? Admit to hospital (regardless of drugs used).
? Undertake comprehensive assessment, including
history of drug and alcohol use. 
? Develop a detailed management plan including
liaison with the general practitioner or community
health professional and plans for discharge.
? If indicated by the woman’s history (such as 
dependence or binge use), initiate or refer for drug 
and alcohol treatment (including pharmacotherapy) 
or counselling (according to the woman’s wishes).
Opioid-using women presenting for the first time in
labour require an urgent assessment of their level 
of opioid tolerance and dependence, as this will
have immediate significance for managing analgesia
during labour and for managing neonatal withdrawal
syndrome. Reassuring the woman that she will be 
treated in a non-judgemental, compassionate manner 
is of great importance and may assist in securing her 
willing participation in antenatal care.
Level of evidence: Consensus
Comment: There is a relationship between antenatal 
care and infant well-being. Late presentation in 
pregnancy may indicate an infant at risk of neonatal 
abstinence syndrome (see section 4, Management of 
neonatal abstinence syndrome (NAS)).
2.2.19 Oral health and risk of preterm birth
There is some evidence that periodontal disease may 
increase the risk of preterm birth. For this reason, and 
until conclusive evidence becomes available, pregnant 
women should be given priority access to dental care. 
Dental infections during pregnancy should be treated 
aggressively by the health service dental health team. 
Routine dental scraping is not recommended as this may 
release bacteria into the circulation.
Level of evidence: Consensus
Comment: Opioid-dependent pregnant women may be 
unaware of pain associated with caries or infection and 
hence not present for treatment of dental problems until 
infection is established. 
2.2.20 Child protection issues
Child protection is governed by the States and 
Territories, not the Commonwealth. Health professionals
in each jurisdiction are advised to consult their relevant 
local legislation.
Assessing infant safety
An assessment of risk to the fetus or infant should be 
made by the health care professional working with the 
family, according to the mandated notification system in
each State or Territory. This assessment should be made 
early in the pregnancy and continue throughout the 
pregnancy and postnatally.
Level of evidence: Consensus
Comment: While operating within the statutory 
framework of each State or Territory jurisdiction, 
clinicians should bear in mind that fear of possible 
intervention by child protection authorities can be 
a significant obstacle to the willing participation in 
antenatal and postnatal care of women with a history 
of drug use. Whatever reassurances and involvement 
can be honestly given to the woman will be useful in 
maintaining trust and in alleviating anxiety. 
Reasons to notify
Child protection agencies are notified when there is
considered to be risk of harm or neglect to a fetus (in
jurisdictions where legislation supports reporting before 
birth) or infant. Reasons for notification will be itemised
in the legislation and protocols in each jurisdiction, but 
generally include one or more of the following:
? late presentation for antenatal care
? polydrug use (including women not using any illicit
drugs, but risky levels of tobacco and alcohol)
? ongoing drug and alcohol use with severe 
mental illness
? unstable living arrangements or homelessness
? suspected abuse
? suspected domestic violence
? concerns regarding parenting practices such as being
in care of an infant when substantially affected by 
drugs or alcohol.
Level of evidence: Consensus
Comment: All health and service providers should be 
alert to the need for intervention, including possible 
child protection notification, if the baby or developing 
child is considered to be at risk of harm. Risk may 
become more evident after discharge from hospital. 
Providers also need to consider the wellbeing of other 
children of the mother and her partner.
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If the statutory child protection agency is notified of a 
child at risk, the health care team should liaise closely 
with the agency throughout the pregnancy and the 
postnatal period. The mother should be informed of the 
notification unless doing so would increase the risk of 
harm to the infant. At appropriate points (such as before 
discharge), case meetings should be conducted. These 
meetings will aim to establish an agreed plan of care for 
the infant, and will include the mother/parents and their
advocates (such as an Aboriginal health worker), as well 
as the child protection worker, health care providers, and 
representatives of all agencies involved in the care of the 
family. At each meeting, a time frame for review of the 
plan should be determined.
Level of evidence: Consensus
Families about whom no notification has been made will
be followed up as usual by the early childhood services
in each State or Territory.
Level of evidence: Consensus
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Obstetric care for women with drug and alcohol use 
issues is provided by midwives and obstetricians who 
are part of the multidisciplinary team providing overall 
pregnancy care.
2.3.1 Early admission in labour
It is suggested that women be advised to attend early 
once they go into spontaneous labour. If elective
induction of labour or caesarean section is planned and 
the woman has complex or unstable drug or alcohol 
use, the time of admission will need to allow for 
assessment and stabilisation before the surgery 
or induction.
Level of evidence: Consensus
Comment: Early admission limits the woman’s need to 
self-medicate at home during labour, and makes it easier 
to monitor her drug use. It is suggested as a proactive 
management strategy.
2.3.2 Monitoring fetal growth
There is an increased risk of reduced fetal growth 
(intrauterine growth restriction) in women who use 
drugs and alcohol. Standard assessment by measuring
symphysis fundal height in centimetres is an adequate 
measure of fetal growth. If that measure indicates
inadequate fetal growth, then the usual obstetric
protocols for biophysical monitoring of reduced fetal 
growth should be followed. 
Level of evidence: Consensus
2.3.3 Out of hours emergency presentations
It is not unusual for pregnant women who use drugs or 
alcohol to present in crisis to emergency services after 
hours, either intoxicated, or in withdrawal, or for social
reasons such as homelessness or violence.
Each health care service requires clear protocols to 
manage these situations so that women are not lost 
to follow-up. The protocols should include which
practitioner is to be notified, and clear guidelines on 
stabilisation and psychosocial management. Jurisdictional
legislation and guidelines to ensure safety must be 
adhered to.
Level of evidence: Consensus 
The comments below on managing withdrawal and 
intoxication in pregnancy should guide protocol 
development. They are also intended to guide
practitioners in the absence of local protocols.
Withdrawal
In the event that the woman is withdrawing from drugs, 
the protocol should specify the following steps:
? Admit the woman as an inpatient .
? Undertake thorough assessment, including drug 
use history and physical signs and symptoms of 
withdrawal.
? If the woman is withdrawing from heroin or other 
opioid drugs, a thorough recent drug use history
must be taken because of the risk of overestimating
or underestimating opioid tolerance. The history
taken also informs decisions about opioid
replacement therapy (if indicated).
? Ascertain whether the woman is in an opioid
treatment program. If so, contact the prescriber, 
clinic or dosing point to find out: 
? the woman’s current dose
? whether she has had her dose that day yet 
? whether she has received takeaway doses.
? If it is confirmed that the woman is opioid
dependent but not in an opioid treatment program, 
and if, after discussion, she gives her informed
consent, she should be inducted into methadone 
maintenance according to the local State or Territory
policy for inpatient induction. This protocol should 
allow for more rapid induction than outpatient
induction, but with close monitoring.
? Legislation and protocols of the local State or 
Territory must be followed.
? Commencing the woman onto methadone 
maintenance should be done in consultation with a 
drug and alcohol medical specialist.
? Methadone is always administered in liquid when 
treating addiction.
? The dose of methadone should be titrated to the 
woman’s symptoms with rapid increases. The starting
dose (inpatient) should be 20mg, reviewed at 4 
hourly intervals. At each review, if the woman has 
objective signs of withdrawal (eg pupils big, restless; 
see Appendix 4: Examples of assessment scales for 
opioid withdrawal in adults), then give an additional
10mg. If there are no signs of withdrawal, no extra 
dose is given until the next scheduled review. The 
maximum dose in the first 24 hours should not 
exceed 50mg. Thirty (30) mg should be more than 
enough for most women, but rarely higher doses will
be necessary, and up to 40mg or even 50mg could 
2.3 Labour and birth
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be required in exceptional cases on day 1. Extreme 
caution should be exercised when assessing the 
patients requirements on subsequent days if a dose 
of over 30mg is used on day 1, in order to prevent 
accumulation and possible toxicity from methadone 
on subsequent days, when this is most likely to occur. 
? The same process should be repeated on Day 2 
(when the woman will almost certainly require less 
methadone), commencing again with 20mg in the 
morning, and giving additional aliquots of 10mg 
as required up to a maximum of 50mg. If at any 
time the woman becomes sedated (small pupils,
drowsiness), increase frequency of observation
and ensure that no methadone is administered 
until sedation is reversed. By Day 3, a reasonable 
idea of the required total daily dose will have been 
established. If prescribing the dose as a split dose, 
give 2/3 in morning, 1/3 in afternoon.
? Depending on local protocols, the assessment of 
opioid withdrawal may be undertaken by a specialist,
a nurse, or a junior medical officer. Health care staff 
without experience in assessing opioid withdrawal
should, in the first instance, seek expert advice,
including telephone advice. Staff who are unable 
in the short term to access expert assistance should 
refer to Appendix 4: Examples of assessment scales 
for opioid withdrawal in adults.
? In rural areas, rapid inpatient induction to 
methadone treatment as described above should 
be used as an acute measure until a review can be 
arranged by the local drug and alcohol unit. Ideally 
this should take no longer than 3 days. When the 
delay in full assessment will be longer than 3 days, 
services should consider transporting the woman 
to a unit with the appropriate expertise to provide
this care.
Intoxication
In the event that the woman is intoxicated, the progress 
of the pregnancy and the condition of the fetus should 
be assessed by the obstetric team. If possible, initial
assessment of the fetus should be by auscultation of 
the fetal heart and cardiotocograph (CTG), with follow-
up ultrasound as considered appropriate. A decision
to admit will depend on circumstances, including the 
gestation (how late in the pregnancy it is), whether there 
has been any antenatal care or investigations, potential
domestic violence, homelessness, concurrent health 
issues and other risk factors. If the service cannot assess 
and manage the woman, she should be transferred 
to a centre which can. If the woman is not admitted,
appropriate support services and referrals, including
pregnancy care follow-up, should be arranged.
Level of evidence: Consensus
2.3.4 Women on an opioid treatment program 
When a woman on a methadone (or buprenorphine)
program presents to give birth, local State or Territory
laws with regard to prescribing and administering the 
drugs must be met. Some jurisdictions may require 
transfer of the permit to prescribe opioids from the usual 
prescriber to the hospital. It is important that the labour 
unit (or other relevant staff) know the correct protocol, 
which must include the following:
? Inform the usual dosing point (whether clinic or 
pharmacy) that the woman is an inpatient and will
not be attending the clinic for dosing.
? Ascertain whether the woman has had her dose 
for that day or is in possession of take-away doses. 
If not, arrangements should be made for her to be 
given her usual daily dose.
? Obtain faxed copies of 
? Confirmation of identity (birth date, address, 
photo, etc)
? Confirmation of last dose (time and size of dose)
? Copy of current prescription for reference by 
hospital prescriber.
? Observe for signs of withdrawal or overdose.
? Before administering the dose, exclude recent opioid
use by taking a recent drug use history.
On discharge, the unit/prescriber and pharmacy should 
be informed by hospital staff of the date of the woman’s 
discharge, and the date and size of the last dose given.
This is particularly important on discharge if the dose has 
been adjusted and is different to the dose on admission.
In some jurisdictions, the permit to prescribe opioids
must be transferred on discharge.
Level of evidence: Consensus 
2.3.5 Induction of labour
There is no indication for an induction of labour if the 
baby is showing normal growth. Induction of labour is
indicated for the normal obstetric and social indications
(including remoteness and access to transport). If 
induction of labour is planned, preferably arrange 
for this to occur early in the week. This will ensure 
the infant is observed closely for signs of neonatal 
abstinence syndrome during the week, rather than on 
the weekend, when experienced staff and neonatal 
specialists may not be readily available.
Level of evidence: Consensus
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2.3.6 Anaesthetic assessment
Consider anaesthetic review in the third trimester to 
discuss venous access and optimum modes of analgesia
for labour, birth and the postpartum period.
Level of evidence: Consensus
Comment: Both analgesic requirements and potential 
crisis situations need to be assessed and anticipated. 
The quality of the relationship already established with 
antenatal staff may influence the extent to which the 
woman will engage with the anaesthetist.
2.3.7 Appropriate forms of pain relief
All forms of pain relief, including non-pharmacological
means, should be offered in labour. If all options have 
been discussed early in pregnancy, informed choices
can be made at this time. Options may include TENS 
machine, water, paracetamol, regional anaesthesia
and epidural, with regard to the usual obstetric
contraindications for each. All forms of pain relief should 
be escalated as required.
Level of evidence: Consensus  
Comment: There is a tendency to underestimate the 
amount of pain relief needed by drug-dependent 
women during labour. Total analgesic requirements 
may be increased in women with a history of drug use. 
Analgesic doses should be individually titrated. Carefully 
assessing the woman’s needs and providing adequate 
and appropriate pain relief is essential. Continuity of 
midwife care and particularly of a known carer has been 
shown to reduce interventions and improve birthing 
outcomes for all women. 
2.3.8 Women on a methadone program in labour
For women in methadone maintenance, the usual 
methadone dose will not relieve the pain of labour. 
Women must receive their methadone dose on 
time (in liquid, not tablet form), but pain must be 
assessed as a separate issue. Dose of analgesic drugs 
should be titrated to response, bearing in mind the 
tolerance to opioids developed during methadone 
maintenance treatment. Pethidine may be ineffective
in women who are opioid or cocaine dependent, due 
to changes in the opiate receptors. Therefore, if non-
pharmacological means of analgesia, or Entonox gas, 
have been ineffective, regional anaesthesia may be 
more appropriate and should be discussed with the 
anaesthetic team on call for labour ward.
Level of evidence: Consensus
Comment: The woman’s methadone dose merely 
inhibits the onset of opioid withdrawal symptoms; 
it is not sufficient to alleviate the pain of child birth.
2.3.9 Women on a buprenorphine program 
in labour
There are no distinctive issues in relation to buprenorphine 
in comparison with methadone. Women receiving
buprenorphine maintenance should be managed as for 
those on methadone maintenance — that is, continue the 
buprenorphine, and give other analgesia (including simple 
analgesics such as paracetamol, and opioids, if indicated)
to manage pain. Full opioid agonists (eg pethidine)
may be less effective due to the pharmacology of 
buprenorphine. The use of regional anaesthesia should 
be considered for the management of pain in labour. For 
further details on managing pain in labour, see the Revised 
National Clinical Guidelines and Procedures for the Use 
of Buprenorphine in the Treatment of Heroine Dependence.
www.nationaldrugstrategy.gov.au/publications/illicit.htm.
Level of evidence: Consensus
2.3.10 Intractable pain
Women in whom pain is difficult to control should 
have pathological causes of pain excluded by 
well-directed investigations.
Level of evidence: Consensus
Comment: Pain caused by an unknown pathology 
may be masked by drug use. Both common (eg 
pyelonephritis) and uncommon (eg sacroiliac joint 
abscess) conditions should be considered when the 
woman’s pain cannot be controlled.
2.3.11 Specific anaesthetic agents to avoid
Among women using, or suspected of using,
psychostimulants, ketamine should be avoided where 
possible because of its catecholamine-related effects 
(such as hypertension and tachycardia).
Level of evidence: IV (Murphy 1993)
Comment: Long term psychostimulant use is associated 
with cardiovascular and cerebrovascular complications 
which can be exacerbated by the use of anaesthetic agents.
2.3.12 Difficulty with venous access
Some drug-dependent women have damaged veins,
making venous access difficult. This may be an indication
for the use of a central venous line. See section 2.3.6.
Level of evidence: Consensus  
2.3.13 Postpartum pain
Pain after surgery such as caesarean section or tubal 
ligation (after vaginal birth) may be difficult to control 
and should be assessed in consultation with the drug 
and alcohol team.
Level of evidence: Consensus
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2.4.1 Timing of discharge
Early discharge is not usually appropriate for drug-
dependent women. Opioid and sedative-dependent
women should be prepared for a postnatal stay of 
five or more days to allow assessment of neonatal 
abstinence syndrome. See also section 4.15.1, Criteria
for safe discharge of infants home.
Level of evidence: Consensus
2.4.2 Contraception
As for all women, options for contraception should 
be discussed before discharge and information
should be provided. It is suggested that the means of 
contraception be reliable and easy to use.
Level of evidence: Consensus
2.4.3 Sudden unexpected deaths in infancy
Sudden unexpected deaths in infancy (SUDI) is the death 
of an infant less than 12 months of age, where the 
death was sudden, and was unexpected at the time.
The term ‘unexpected’ indicates that the cause of death 
was not recognised before the event, although it may 
be diagnosed at autopsy . SUDI usually includes death 
due to SIDS and to other ill-defined causes (such as 
sleeping accidents).  
SIDS and tobacco
Both maternal smoking during pregnancy and 
environmental exposure of the infant to tobacco smoke 
(ETS) are associated with an increased risk of sudden 
infant death syndrome (SIDS). 
All parents should be advised of the association between 
environmental tobacco smoke and SIDS. Mothers who 
smoke tobacco (or cannabis mixed with tobacco), or 
who live with smokers, should be advised of these risks,
and specifically:
? not to smoke during feeding (whether breastfeeding
or bottle feeding)
? not to smoke in the house or the car with the baby
? that partners, family and friends should not smoke in
the house or the car.
In addition, mothers should be offered support with
smoking cessation.
Level of evidence: Consensus
An infant’s’ most harmful exposure to tobacco is
through environmental tobacco smoke. Smoking
outside the home and away from the infant reduces 
the infant’s exposure. Contamination by environmental 
tobacco smoke is not limited to the indoor air, it includes
surfaces and dust in living rooms and bedrooms and 
on skin. Infants are at risk of exposure to the toxic
components of environmental tobacco smoke through 
these sources, so it is important that parents are given
this information. Refer to section 3.2.9, Environmental 
tobacco smoke.
Level of evidence: IV
Sleeping practices
Cosleeping, or ‘bed-sharing’ refers to the infant sleeping
in the same space as an adult — whether bed, lounge 
or floor. There is a risk of 
? accidental smothering of the infant
? injury to the infant
? the adult not waking if the infant becomes 
distressed.
All women should be informed of these risks and about 
safe sleeping practices before discharge.
Level of evidence: Consensus
Aboriginal and Torres Strait Islander women
All health care workers should be aware that mothers 
or other family members sleeping with infants is a 
common practice in Aboriginal and Torres Strait Islander 
communities. Culturally appropriate education should be 
provided in relation to the risks. Sids and Kids provide an 
Indigenous brochure on safe sleeping practices at 
http://www.sidsandkids.org/safe_sleeping_parents.html
Level of evidence: Consensus
Sedating substances and sleeping accidents
In particular, if an adult has used any form of sedating
substance which might result in them sleeping heavily
(including prescription medications, methadone and 
alcohol), there is an increased risk to the infant. A 
woman who drinks alcohol or takes sedating substances 
before sleeping should be advised
? not to have the baby sleep with her 
? that if she is heavily sedated, she may not wake 
for the baby’s next feed, or if the baby becomes 
distressed
? to consider arranging a ‘safety plan’. That is, to have 
another responsible adult to take care of the infant if
the mother decides to use drugs or alcohol.
2.4 Postnatal care
National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn  PAGE 17
Any other person responsible for caring for the baby 
should also be informed about these risks and about 
safe sleeping practices.
Level of evidence: Consensus 
Comment: Information will ideally be given both verbally 
and in writing. For an example of a parent education 
brochure on safe sleeping practices for women using 
drugs, alcohol or sedating medication, see Appendix 5: 
Examples of safe sleeping practices information. Refer 
also to section 3.2.9, Environmental tobacco smoke.
Safe sleeping practices
All women should be provided with a general SIDS 
brochure as well as information related to drug and 
alcohol use and sleeping practices. More detailed
information on safe sleeping practices can be found 
on the Sids and Kids website at 
http://www.sidsandkids.org/safe_sleeping-parents.html 
Advice to parents should include the following:
? Put baby on the back to sleep.
? Sleep baby with face uncovered.
? Baby sleeps in own sleeping space, not an adult bed.
? Baby should have  a safe cot, safe mattress, and 
safe bedding.
? Put baby’s feet at the bottom of the cot, tuck 
bedclothes in firmly.
? Tobacco smoke is bad for baby.
Level of evidence: Consensus 
2.4.4 Preparation for discharge
A timely and thorough written discharge plan, initiated
during pregnancy, must be reviewed with the woman 
and care providers before discharge. The plan must 
take into account assessments commenced in the 
antenatal period:
? parenting ability
? stability and psychosocial issues
? mental health
? environmental issues including safe storage of 
medications in the home
? material goods and preparation for the baby
? child protection issues.
Copies of the plan are placed in the mother’s notes, 
the infant’s notes and given to the mother. The plan 
needs to include appointment dates and contact details,
which are given to the mother and forwarded to 
community providers.
Level of evidence: Consensus
For examples of two discharge checklists, see Appendix
6: Examples of discharge assessment checklist.
2.4.5 Assertive follow-up
Inpatient services
Babies of mothers with a history of problematic drug 
or alcohol use need the same support and follow-up as 
other babies. The mother may require support to access 
appointments with the baby, such as help with transport 
or finances. At the time of discharge, there must be 
a formal transfer of responsibilities from the hospital
to the community services that will be continuing
care, and referrals and supports must be in place. The 
provider who is referring should actively follow up with
community services to ensure that the woman has 
engaged with the service. Where engagement has not 
occurred, the referring provider should follow up with
the woman/family. 
Level of evidence: Consensus
Community services
In accepting the referral, the community provider/service
should be aware that families with drug and alcohol use 
issues may be difficult to engage in care. Community
services must be active in engaging these families
and ensuring arrangements are followed up. These 
arrangements might include appropriate assessment, 
care and support services to ensure the wellbeing
of the mother and baby, and to identify ongoing
developmental issues.
Level of evidence: Consensus
Comment: At all points of contact, there should be 
ongoing risk assessment regarding the wellbeing and 
safety of the infant and/or other children. This may 
involve referral to child protection services (see section 
2.2.20, Child protection issues).
2.4.6 Home visiting
An in-home assessment may be required before 
discharge, but most families will not receive home 
visiting on an ongoing basis. Families should be assessed 
individually as to the appropriateness and likely benefits
of in-home visits.
Level of evidence: Consensus
Comment: Although there is currently insufficient 
evidence regarding the efficacy of sustained home 
visiting in women with serious substance misuse, 
in-home visits are one method of providing care and 
support to mothers and families, particularly those who do
not engage well with community and hospital services.
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2.4.7 Early intervention programs
It may be important to intervene early for children 
affected by parental drug and alcohol use, particularly
children diagnosed with fetal alcohol syndrome. 
There is insufficient evidence at this point to draw 
firm conclusions, but it is important that parents are 
supported to engage with their children in ways that 
promote all aspects of the child’s development.
Level of evidence: Consensus
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2.5.1 General principles
Mothers who are drug dependent should be encouraged 
to breastfeed with appropriate support and precautions.
In addition, it is now recognised that skin-to-skin contact 
is important regardless of feeding choice and needs 
to be actively encouraged for the mother who is fully 
conscious and aware and able to respond to her 
baby’s needs.
Level of evidence: Consensus
Comment: Breastfeeding is recognised as the best 
nutrition for the infant. It is also inexpensive and easier 
to prepare and deliver than other options. As with all 
mothers of newborns, breastfeeding is recommended, 
where possible, for drug-dependent mothers, with the 
cautions described in the following statements. 
A harm minimisation approach to breastfeeding
is recommended in these guidelines. Encouraging
breastfeeding is preferred to avoiding breastfeeding,
provided that:
? the woman is informed about the likely effects on 
the infant of the drugs she is using (or may use) and
? the woman is assisted to plan minimum exposure of 
the infant to the effects of these drugs.
Level of evidence: Consensus
Comment: In these guidelines, a ‘harm minimisation 
approach’ does not mean that the woman should be 
advised against breastfeeding.
In advising drug-dependent women with regard to 
breastfeeding, the specific potential risks in each 
woman’s individual circumstances should be weighed
against the benefits of breastfeeding, and she should be 
informed of them.
Level of evidence: Consensus
Comment: There is very little evidence about the effects 
of most drugs, prescription and licit as well as illicit, 
when administered to an infant through breastfeeding. 
Much more evidence is needed. 
Hale (2004) provides a rating system for categorising
the risk posed by drugs when administered to an infant
through breastfeeding (See Appendix 7: Categorisation
of drug risks in pregnancy and breastfeeding).
As with all breastfeeding women, drug-dependent 
women should not wean rapidly. 
Level of evidence: Consensus
Comment: The level of methadone in breastmilk is 
low when the mother is on a methadone maintenance 
program, and does not affect the infant’s blood level 
of methadone. 
2.5.2 Breastfeeding and tobacco
Minimal amounts of nicotine are excreted into breast 
milk and absorption of nicotine through the infant’s gut 
is minimal, but tobacco smoking can have other effects 
on breastfeeding that might indirectly affect the baby. 
Women should be informed that:
? milk production may be reduced by as much as 
250 mL per day in mothers who smoke
? mothers who smoke are less likely to start 
breastfeeding than non-smokers
? that mothers who smoke tend to breastfeed for 
a shorter time.
Level of evidence: Consensus in British Medical 
Association 2004.
Comment: This information must be given to the 
woman in the context of discussing the substantial 
benefits to both the infant and mother of breastfeeding. 
There may be broader psychosocial issues affecting the 
woman’s ability to breastfeed, and it would be helpful 
to assist the woman to identify and address these.
2.5.3 Breastfeeding and nicotine replacement 
therapy (NRT)
Women who wish to breastfeed while continuing to 
use nicotine replacement therapy should be advised to 
breastfeed first, then, as soon as possible after feeding,
use one of the intermittent delivery methods of NRT 
(inhaler, gum, lozenge or sublingual tablet). This will
maximise the time between use of NRT and the next 
feed, and reduce the baby’s exposure to nicotine.
Level of Evidence: Consensus
Comment: Nicotine is both water and lipid soluble and 
distributes rapidly to and from breast milk, but little is 
likely to be absorbed by the infant. As maternal plasma 
nicotine concentration rises and falls, the same occurs in 
breast milk. The mean elimination half-life of nicotine in 
breast milk is 95 minutes. Even if the mother is using a 
high level of NRT, the infant’s daily exposure (normalised 
for the weight of the infant) is less than 2 per cent of 
the exposure of the mother. It is unlikely that such low 
levels of exposure are harmful to the infant. In contrast, 
there is good evidence that exposure to environmental 
tobacco smoke is harmful to the infant. Therefore, 
2.5 Breastfeeding
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providing NRT to the mother, if this results in her not 
smoking, is of great potential benefit to the baby. 
The formulation of NRT used may affect the level 
of nicotine in breast milk. The nicotine transdermal 
patch provides a steady level of nicotine in plasma and 
therefore in breast milk and the mother has no control 
over the level of nicotine in the milk. Mothers who 
use intermittent delivery systems of NRT may be able 
to minimise the nicotine in their milk by prolonging 
the duration between nicotine administration and 
breastfeeding. (Level of Evidence to support Comment: 
III-2 Dempsey and Benowitz 2001)
2.5.4 Breastfeeding and alcohol 
The Australian Alcohol Guidelines recommend 
a prudent approach to breastfeeding if alcohol 
is consumed www.alcoholguidelines.gov.au/index.htm:
Women who are breastfeeding are advised not to 
exceed the levels of drinking recommended during 
pregnancy, and may consider not drinking at all.
If a breastfeeding mother wants to drink alcohol, it is
suggested that she breastfeed before drinking alcohol, 
then wait a minimum of three to four hours after the 
last drink before breastfeeding again. In the event 
that the woman exceeds the recommended levels of 
drinking, it is suggested that she wait approximately
three hours per standard drink consumed before 
breastfeeding again. She may consider expressing and 
storing breastmilk prior to drinking.
Comment: Metabolism of alcohol varies with individual 
differences, such as weight and liver function, making 
it difficult to be prescriptive about the amount of time 
needed for the mother’s blood alcohol to return to zero. 
Alcohol does not remain in breastmilk, but diffuses back 
into the mother’s circulation as her blood level drops. 
Consequently there is no need for her to express and 
discard milk as long as she waits until her blood alcohol 
returns to zero to breastfeed her baby again. Although
there is very little research evidence about the effect of 
alcohol on the infant, there are reports that even low 
levels may reduce the supply of milk and cause poor 
feeding with irritability and sleep disturbance in the 
infant. See also Appendix 8: Australian Alcohol Guidelines: 
pregnancy and breastfeeding for more information.
2.5.5 Breastfeeding and opioids
Mothers who are stable on methadone treatment 
programs should be supported if they choose 
to breastfeed.
Level of evidence: Consensus 
Comment: Women who are stable on methadone, but 
may occasionally use heroin, in a ‘one-off’ pattern, 
should be advised to express and discard breastmilk for a 
24 hour period afterwards, then return to breastfeeding. 
This is not an indication for ceasing breastfeeding. The 
mother should consider having a ‘safety plan’ for the 
infant on such an occasion. This may include expressing 
and storing breastmilk in advance, or preparing formula, 
as well as having a responsible adult care for the infant.
Mothers who are unstable, continuing to use short 
acting opioids such as heroin, or using multiple drugs, 
should be encouraged not to breastfeed, and attention
should be paid to assisting them to stabilise
their lifestyle.
Level of evidence: Consensus 
Comment: An unstable pattern of drug use may raise 
child protection concerns (see section 2.2.20, Child 
protection issues).
The safety of buprenorphine is not yet established for 
breastfeeding. Women who choose to breastfeed while
taking buprenorphine, and can make an informed
decision, should be informed of the risks and supported 
in their decision. The amount of buprenorphine in
breastmilk is small and considered to be clinically
insignificant.
Level of evidence: Consensus 
2.5.6 Breastfeeding and benzodiazepines
Potential risks should be weighed up against
benefits of breastfeeding when the mother is using
benzodiazepines. If a woman taking benzodiazepines
wishes to breastfeed, she should be advised that she 
should not stop taking the benzodiazepines abruptly, 
but should undergo supervised gradual withdrawal if
she wishes to cease use.
Women on short-acting benzodiazepines should be 
advised not to breastfeed immediately after taking
a dose because of the dual risk of her falling asleep, 
potentially smothering the infant, and of the infant
receiving a maximum dose and becoming excessively
drowsy. If the mother does breastfeed while she is
drowsy, she should be sure she is securely seated 
in a chair (not lying down), with the baby also well 
supported, so that if she falls asleep the baby will be 
safe (see section 2.4.3, Sudden unexpected deaths in
infancy (SUDI)).
Level of evidence: Consensus
Comment: The safety of benzodiazepines in breast 
milk is not known. Ideally, pregnant women will 
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have undergone progressive supervised withdrawal 
throughout the pregnancy (see section 3.8, 
Benzodiazepines) and will not be taking benzodiazepines 
while breastfeeding.
2.5.7 Breastfeeding and psychostimulants 
Potential risks should be weighed against the 
benefits of breastfeeding when the mother is using
psychostimulants. A mother who wishes to breastfeed 
should be supported in that decision, unless she is a 
regular user and is unstable, in which case she should 
be advised against breastfeeding. Breastfeeding mothers 
who use psychostimulants rarely or in binges, must be:
? informed of the risks
?  educated in how to avoid the harmful effects to 
the baby, that is:
? to express and discard the breast milk after 
psychostimulant use (not to simply stop 
breastfeeding)
? to have a supplementary feeding plan ready 
for such eventualities
? advised not to breastfeed for 24 hours after 
the use of amphetamines, ecstasy or cocaine.
Although cocaine has a shorter duration of action
than amphetamines, the illicit drug may be mixed
with other unknown substances, so a 24-hour 
delay is recommended. 
Level of evidence: Consensus
Comment: Ecstasy is an amphetamine derivative. The 
half life is likely to be brief, less than eight hours, but 
dependent on dose. Because the structure is similar to 
methamphetamines it is likely that it is transmitted via 
breastmilk. It is not known when it is safe to reinstate 
breastfeeding after use but 24 hours should be sufficient.
2.5.8 Breastfeeding and cannabis
Potential risks should be weighed up against the benefits
of breastfeeding. There is insufficient evidence to make 
an evidence-based recommendation about cannabis and 
breastfeeding. There is some evidence that cannabis is
excreted in breast milk, but the effects on the infant
are unknown.
Cannabis is a long acting drug, so advice to take the 
drug after breastfeeding (as for alcohol) is not useful. 
Current advice given to women ranges from supporting
the decision to breastfeed to advising against it. Heavy 
use of cannabis may pose a greater risk of transmission
in breast milk, but this is not known.
Level of evidence: Consensus
Advice to mothers and others should be as for tobacco: 
that is, smoke away from the infant, out of the house, 
and not in the car.
Level of evidence: Consensus
2.5.9 Breastfeeding and blood-borne viruses
Human immunodeficiency virus
Breastfeeding increases the risk of transmission of HIV 
from mother to infant, particularly during the first
6 months. HIV-positive mothers should completely 
avoid breastfeeding and use formula milk instead. It 
is important that women who are not breastfeeding
be informed of the benefits to the infant of 
skin-to-skin contact.
Level of evidence: III-2
Comment: Replacing breastfeeding with formula milk is 
a safe practice in Australia, where safe water and good 
quality infant formula are readily available. The role 
of antiretroviral therapy during breastfeeding is yet to 
be determined in communities where formula feeding 
carries a substantial risk.
Hepatitis C virus
There is no evidence that breastfeeding increases the 
risk of transmission of hepatitis C from mother to infant.
Women should be informed of the theoretical risks
and discard breast milk if it may be contaminated with
blood, such as by cracked, abraded or bleeding nipples.
Level of evidence: III-2
Comment: While encouraging HCV-positive women 
to breastfeed, it is essential that the woman make an 
informed decision. The information that should be 
provided includes:
? that the virus does appear in breastmilk
? that (in the absence of HIV co-infection, which can 
increase HCV viral load) the risk of transmission 
appears to be small
? that transmission may depend on viral load
? that transmission is not via the gastrointestinal tract, 
but is blood-borne.
Hepatitis B virus
There is no evidence that breastfeeding increases the 
risk of transmission of Hepatitis B from mother to infant.
To protect against transmission it is extremely important
that all infants of HBsAg (hepatitis B surface antigen)
positive mothers receive active and passive immunisation
within 12 hours after birth.
Level of evidence: III-2
Comment: Although HBV DNA and HBsAg have 
PAGE 22  National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn
been detected in breast milk, no additional risk with 
breastfeeding has been demonstrated.
2.5.10 Lactation advice
Advice should be sought from a child and family health 
nurse, a lactation consultant or a midwife with drug and 
alcohol experience where there is uncertainty about how 
to advise the drug-dependent mother with regard to 
breastfeeding.
Level of evidence: Consensus 
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2.6.1 General considerations
Confidentiality
Confidentiality of information must be assured to 
women and partners.
Level of evidence: Consensus
Occupational health and safety of staff
Issues affecting the occupational health and safety of 
staff should be considered in the management of people 
with blood-borne viruses.
Level of evidence: Consensus
Comment: Normal body fluid precautions should be 
taken, bearing in mind that infectivity may be related to 
viral load.
Education
In line with the national strategy on drug use, education
about safe sex and risk reduction practices is vital in
preventing blood-borne viral infections.
Level of evidence: Consensus
Comment: This applies to all people using health 
services. All women of childbearing age should be given 
information about blood-borne viral infections in relation 
to pregnancy.
Screening
Refer to section 2.2.4 Screening: Screening for blood-
borne viruses.
Breastfeeding
Refer to section 2.5.9, Breastfeeding and 
blood-borne viruses.
2.6.2 Human immunodeficiency virus
Antiretroviral therapy
Antiretroviral therapy reduces the risk of vertical
(mother-to-child) transmission. It should commence 
after the first 12 weeks’ gestation and be maintained
during pregnancy. Combination therapy is more effective
than single agent therapy at preventing perinatal
transmission. Consult an infectious diseases specialist for 
further detail.
Level of evidence: II
Comment: Evidence suggests micro-transfusion may 
occur during fetal life. The risk of HIV vertical 
transmission is significantly reduced if zidovudine 
is given during pregnancy (from 25 per cent risk in 
the placebo group to 8 per cent in the zidovudine 
group). It is further reduced by combination therapy. 
There is concern regarding the teratogenicity of some 
antiretroviral drugs during early gestation. Consult an 
infectious diseases specialist for the management of 
antiretroviral therapy in pregnancy.
Caesarean section —  Reducing risk at birth 
Elective caesarean section can reduce the risk of 
perinatal transmission to the infant. This should be 
discussed and offered.
Level of evidence: II-1
Exposure of the infant to maternal secretions at 
birth should be minimised by avoiding invasive fetal 
monitoring and promptly cleaning and bathing the 
infant soon after birth.
Level of evidence: Consensus
Comment: It appears that vertical transmission mostly 
occurs during the last week of pregnancy and during 
birth. The risk can be reduced by elective caesarean 
section, avoiding exposure to maternal secretions during 
birth, and refraining from invasive fetal monitoring. 
Intravenous antiretroviral therapy should be given before 
the birth.
Antiretroviral therapy and the newborn
Antiretroviral therapy for the newborn is recommended 
as soon after birth as possible and for the first 6 weeks 
of life.
Level of evidence: Consensus
Comment: Choices of drug therapy depend on the 
maternal viral load determined by PCR test at or close to 
birth. Combination therapy is considered more effective 
than single agent therapy. Up-to-date advice should 
be sought from a paediatric HIV specialist or infectious 
diseases specialist.
Immunisation
Advice should be sought from a paediatric HIV specialist
or infectious diseases specialist for other measures such 
as prophylaxis against Pneumocystis and modification of 
immunisation schedules.
Level of evidence: Consensus
2.6 Vertical transmission of blood-borne viruses
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Monitoring
Monitoring of HIV status by PCR testing to exclude 
vertical transmission should be extended to the first 18 
months of life.
Level of evidence: Consensus
Comment: Blood tests in the infant should show a 
decline of transplacental antibodies (ie maternal HIV 
antibodies), but vertical transmission cannot be excluded 
by testing during the first 12–15 months. Advice from 
a paediatric HIV specialist should be sought in line of 
evolving new evidence. 
2.6.3 Hepatitis C virus
Caesarean section
Caesarean section has not been shown to reduce HCV 
transmission. Recommending caesarean section to 
prevent vertical transmission is not justified.
Level of evidence: Consensus
Monitoring
Currently infants are tested for hepatitis C at 18 months 
of age, when transplacental antibodies will have 
disappeared from the infant’s blood. If the parents are 
very anxious about possible vertical transmission from 
mother to baby, PCR testing may be offered from the 
age of 4–6 months. Testing should be organised to 
coincide with other postnatal checks.
Level of evidence: Consensus
Comment: Some parents experience high levels of 
anxiety while waiting to find out whether their child 
has hepatitis C. In such cases, the choice of whether 
to test early should always be made by the parents. If 
PCR testing for HCV-RNA is negative at 4–6 months of 
age, infection is very unlikely (although not impossible). 
HCV antibody testing to confirm negative status is 
recommended at 18 months of age (when maternal 
HCV antibody will no longer be detectable). On the 
other hand, some parents may prefer not to have earlier 
testing because of experiences of discrimination and fear 
of being blamed for transmitting the virus to the infant.
Any testing of babies should be accompanied by 
thorough counselling of parents before and after 
the test.
Level of evidence: Consensus
Mother-to-child transmission is demonstrated by the 
detection of HCV antibodies in the infant beyond 18 
months of age, or HCV RNA by PCR at 4-6 months 
of age.
Level of evidence: Consensus
Comment: The responsibility for following this up lies 
with the woman’s primary health carer, who will often 
be her general practitioner.
Managing vertical transmission
Infants with confirmed HCV infection should be 
referred to a paediatric hepatologist or infectious
disease specialist.
Level of evidence: Consensus
2.6.4 Hepatitis B virus
Caesarean section
With the availability of passive and active immunisation
for infants at birth, elective caesarean section to reduce 
risk of vertical transmission is not justified.
Level of evidence: Consensus
Vaccination 
Women who are HBsAb negative should be offered HBV 
vaccination after birth.
Level of evidence: Consensus
Comment: It is public health policy in Australia that all 
newborns receive HBV immunisation. In addition, babies 
of HBsAg positive mothers are given immunoglobulin.
National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn  PAGE 25
3.1 Alcohol 26
3.2 Tobacco 28
3.3 Opioids 34
3.4 Methadone 35
3.5 Buprenorphine 38
3.6 Naltrexone 39
3.7 Cannabis 40
3.8 Benzodiazepines 41
3.9 Amphetamines 42
3.10 Cocaine 43
3.11 Inhalants 44
Specific drugs in pregnancy 3
PAGE 26  National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn
3.1.1 Harmful effects of alcohol
Alcohol is known to have teratogenic effects. Drinking
alcohol while pregnant increases the risk of problems 
in fetal development, but the level of drinking which
causes significant fetal problems is not known. In this
document, the term ‘fetal alcohol spectrum disorder’ 
(FASD) is used to indicate the full range of possible
effects of fetal exposure to alcohol, while the term 
‘fetal alcohol syndrome’ (FAS) will be used to indicate
the severe effects, characterised by brain damage, facial
deformities, and growth deficits.
Screening
Refer to section 2.2.5, Screening.
3.1.2 Advice on drinking alcohol in pregnancy
All pregnant women should be given information on the 
risks associated with drinking alcohol during pregnancy 
and advised that no completely safe level of alcohol 
consumption has been determined for the fetus.
Level of evidence: Consensus
Comment: The Australian Alcohol Guidelines note that 
the first few weeks after conception, before the first 
missed period, are probably the most crucial in relation 
to alcohol. At that time it is unlikely the woman will 
know she is pregnant, particularly if the pregnancy is 
unplanned. For this reason, there is a strong need for 
education about safe drinking for all women of child 
bearing age, including young women still at school. This 
education should include a discussion of the risks of 
binge drinking as well as other patterns of drinking.
From Australian Alcohol Guidelines: Health Risks and 
Benefits (NHMRC, 2001, p.16). www7.health.gov.au/
nhmrc/publications/_files/ds9.pdf:
NH&MRC GUIDELINE 11: Women who are pregnant 
or might soon become pregnant 
11.1 may consider not drinking at all.
11.2 most importantly, should never become intoxicated.
11.3  if they choose to drink, over a week, should have 
less than 7 standard drinks, AND, on any one day, 
no more than 2 standard drinks (spread over at 
least two hours).
11.4 should note that the risk is highest in the earlier
stages of pregnancy, including the time from 
conception to the first missed period.
See also Appendix 8: Australian Alcohol Guidelines: 
pregnancy and breastfeeding for more information.
Comment: These guidelines currently concur with the 
national guidelines developed by the NHMRC for alcohol 
consumption by pregnant women, although it is noted 
that the NHMRC guidelines do not classify a level of 
evidence to support its recommendations. 
An abstinence-based approach is not recommended, in 
part because it could result in disproportionate anxiety 
among women with an unplanned pregnancy, many of 
whom consume some alcohol before they know they 
are pregnant, but usually without harmful consequences 
for the infant. Anxiety about alcohol consumption has 
sometimes resulted in precipitous decisions to terminate 
a pregnancy1.  
The ‘standard drink’ measure of 10 g of alcohol should 
be used in assessing the level of alcohol consumption.
This measure should be explained to the woman and her 
partner if present. 
Level of evidence: Consensus  
Comment: There is a need for better education of both 
the public and health care workers on what defines 
a standard drink in Australia (that is, 10 g alcohol). In 
addition, there is a need for specific education of health 
care workers about the Australian Alcohol Guidelines. 
Information about standard drinks and how to calculate 
the alcohol content of different alcoholic drinks can be 
found at www.alcohol.gov.au/guidelines/standard.htm.
3.1.3 Aboriginal and Torres Strait Islander women
Health care workers must become familiar with local 
drinking habits, patterns and terminology (eg ‘charged 
up’, ‘nugu’) to ensure accurate assessment of risk and 
its management.
Level of evidence: Consensus
Comment: Patterns of consumption of alcohol vary 
markedly in Aboriginal and Torres Strait Islander 
communities from non-Indigenous communities: 
Aboriginal and Torres Strait Islander communities 
have higher proportions of both non-drinkers and of 
hazardous/harmful drinkers. Assessment can be difficult 
because heavy drinking and group drinking are often the 
norm (that is, involving more than half the community) 
and are related to external factors, such as canteen 
hours and ‘pay days’. Therefore, alcohol consumption 
can be difficult to quantify in terms of standard drinks. 
1 See National Report Fetal Alcohol Syndrome National Workshop 2002.
Australian National Council on Drugs and National Expert Committee
on Alcohol.
3.1 Alcohol
National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn  PAGE 27
Nevertheless, it can be categorised according to the 
Australian Alcohol Guidelines risk categories 
www7.health.gov.au/nhmrc/publications/_files/ds9.pdf.
3.1.4 Access to treatment
Pregnant women identified as consuming risky levels of 
alcohol (as defined in the Australian Alcohol Guidelines)
should have priority access to alcohol treatment services,
including comprehensive assessment and detoxification,
but also including therapeutic options such as brief
intervention, cognitive behavioural therapy and 
group sessions.
Level of evidence: Consensus
The need for detoxification is an indication for inpatient
admission and treatment. Pregnant women who 
require alcohol detoxification should be admitted into
a supportive health care environment and provided
with continuity of care, including ongoing counselling.
Women who are withdrawing from alcohol should be 
supported with medication and nutritional and vitamin
supplementation and should have access to appropriate
maternal and fetal monitoring. The therapeutic
environment should be sensitive to gender and cultural 
issues that influence the acceptability of treatment.
Level of evidence: Consensus
3.1.5 Neonates and infants
Neonates who have been exposed to regular excessive
maternal alcohol consumption in utero are monitored 
for withdrawal symptoms during their first days of life.
Appropriate supportive care and medications to treat 
withdrawal symptoms will be available to these babies.
Level of evidence: Consensus
Comment: Babies will withdraw 24–48 hours after birth 
if the mother is intoxicated at birth. Refer to section 
4.11.2, Treatment of non-opioid withdrawal.
Neonates whose mothers have engaged in risky levels 
of drinking (as defined in the Australian Alcohol 
Guidelines), or those whose mothers have given birth
previously to a baby with FAS should be assessed at 
birth for signs of FAS, and followed up for at least the 
first 6 months by a health professional with specialist
knowledge of FAS.
Level of evidence: Consensus
Comment: Few affected babies have clear physical signs 
of FAS at birth and diagnosis is difficult. In suspected 
cases, the infant should be reassessed at about 6 
months of age.
Infants/young children who demonstrate signs of FASD 
should be followed up regularly in the community by 
an appropriately trained health professional, during
pre-school and early school life (that is, up to at least 
7 years of age). If the mother is identified during
pregnancy as a high risk alcohol user, then she should be 
offered interventions and support to ensure continuity of 
care to both mother and child.
Level of evidence: Consensus
Comment: There is evidence from the US to suggest 
that early intervention for infants with FAS improves 
long term educational outcomes.
Children with alcohol-related neurodevelopmental 
disorders (ARND) should have access to appropriate
assessments and ongoing support within the health 
and education services (that is, with professionals
experienced in these issues).
Level of evidence: Consensus
When children present for paediatric assessment with
attention deficit hyperactivity disorder (ADHD), an 
adequate history of parental antenatal alcohol intake
should be taken. 
Level of evidence: Consensus
Comment: Alcohol-related neurodevelopment disorders 
may be an under-recognised condition. Children 
diagnosed with ADHD could have alcohol-related 
neurodevelopment disorders, but an adequate history 
is not usually taken. The difficulty is that if ADHD is 
diagnosed at (for example) age 10, more than 10 years 
has elapsed since the potential fetal exposure. The 
mother’s history of alcohol use is unlikely to be reliable 
after this lapse of time.
3.1.6 Naltrexone
Refer to section 3.6, Naltrexone.
Breastfeeding 
Refer to section 2.5, Breastfeeding.
Safe sleeping practices
Refer to section 2.4.3, Sudden unexpected deaths in
infancy (SUDI).
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3.2.1 Harmful effects of tobacco 
The harm caused by tobacco smoking during pregnancy 
is well established, and includes an increased incidence
of threatened and spontaneous miscarriage, premature 
birth, low birth weight for gestational age, perinatal
death, SIDS, and other longer-term effects on the health 
of the child.
Comment: There is substantial evidence that tobacco 
poses a great risk to both the mother and the fetus. 
Abstinence early in pregnancy will give the greatest 
benefit to mother and fetus; stopping smoking at any 
point during pregnancy is beneficial. Pregnancy may be 
an opportunity to improve health outcomes for women 
who smoke. It is a time when many are in regular 
contact with health professionals and are motivated to 
stop smoking. 
Fertility
Smoking reduces fertility in both men and women. 
Studies have shown that smoking makes it more difficult
for women to become pregnant. Women who are 
trying to conceive should be advised and supported 
to quit smoking. In men, smoking increases the risk of 
impotence and reduces the quality of semen. Men who 
smoke have a lower sperm count than non-smokers, and 
their semen contains a higher proportion of malformed 
sperm and sperm with reduced motility. 
Level of evidence: III-2 in US Surgeon General’s Report 2004 
and consensus in British Medical Association 2004
Comment: Women who quit smoking should be 
informed of the possibility of increased fertility. 
This includes women on methadone programs who 
stop smoking. 
3.2.2 Interventions
If possible, information and services for smokers should 
be integrated into existing services dealing with sexual, 
reproductive and child health. These include maternity
services, male health clinics, well women clinics, cervical
screening services, centres for reproductive medicine,
child health clinics, Aboriginal medical services and drug 
and alcohol services.
Level of evidence: Consensus in British Medical 
Association 2004
Pro-active telephone counselling is effective in
increasing smoking cessation rates when used as 
a sole intervention or when augmenting programs 
initiated in hospitals.
Level of evidence: I (Miller and Wood 2002)
Comment: Many Quitlines in Australia now provide 
expert support throughout a quit attempt through 
a free callback service. The Quitline service can be 
contacted on 13 7848 (13 QUIT) for the cost of a local 
call from anywhere in Australia.
Smoking cessation during pregnancy improves birth
outcomes including rates of low birth weight for 
gestational age, rates of pre-term birth and mean 
birth weight.
Level of evidence: Consensus in British Medical Association
2004; US Surgeon General’s Reports 1990 and 2004)
Smoking cessation programs in pregnancy appear to 
reduce smoking, low birthweight and preterm birth,
but no effect was detected for very low birthweight or 
perinatal mortality.
Level of evidence: I (Cochrane review: Lumley et al 2001) 
Screening 
Refer to section 2.2.5, Screening.
3.2.3 Assessment of dependence
If the screening is positive:
? Ask the woman about her understanding
regarding the potential harmful effects of 
smoking on the fetus.
? Discuss in a collaborative way:
? the benefits of stopping smoking for her 
and the fetus
? the options and support for quitting smoking
? the availability of nicotine replacement therapy 
and when it is appropriate
? the risks of passive smoking to her and the fetus, 
especially if her partner smokes.
Level of Evidence: Consensus
Comprehensive assessment
A comprehensive assessment of all smokers is
recommended, including their motivation to quit,
degree of nicotine dependence and presence of barriers
to cessation. The revised Fagerström Test for Nicotine
Dependence (FTND) is a simple 6-question tool for 
assessing level of nicotine dependence and may be 
3.2 Tobacco 
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useful as an indication of whether pharmacotherapy 
may be required to support a quit attempt. Two 
questions in the FTND have been biochemically
validated: cigarettes per day (CPD) and ‘time to first
cigarette’ (TTFC). See Appendix 9: Fagerström test for 
nicotine dependence.
Level of evidence: IV (Heatherton et al 1991).
Comment: CPD does not on its own give an adequate 
assessment of nicotine dependence, and should not be 
relied on by clinicians. Variations in the levels of nicotine 
in cigarettes, and restricted social opportunities to 
smoke, have resulted in a change in smoking behaviour 
to compensate. Compensatory smoking behaviour to 
increase the level of nicotine in the blood includes taking 
more inhalations per cigarette, holding the smoke in the 
lungs longer, and smoking cigarettes closer to the butt 
before extinguishing them. 
TTFC: Smokers who are more highly nicotine dependent 
are more likely to wake up in the morning feeling 
‘nicotine-deprived’, have their first cigarette earlier after 
waking and smoke more in the morning than smokers 
who are less dependent. Asking about ‘time to first 
cigarette’ (after waking) (TTFC) can provide a useful 
indicator of nicotine dependence. Those who smoke 
their first cigarette of the day within 30 minutes of 
waking and also smoke 15 cigarettes or more per day 
are likely to have more difficulty in quitting and may 
require more intensive support.
Brief assessment
Where a comprehensive assessment is not possible,
nicotine dependence can be assessed by asking:
1 How many minutes after waking to first cigarette?
2 Number of cigarettes per day?
3 What cravings or withdrawal symptoms in previous
quit attempts?
? Smoking within 30 minutes of waking, smoking
more than 15 cigarettes per day and a history of 
withdrawal symptoms in previous quit attempts are 
all markers of nicotine dependence.
? Nicotine replacement therapy for dependent smokers 
is proven to double the chances of successfully 
quitting. All commercially available forms of NRT 
are effective as part of a strategy to promote 
smoking cessation.
Level of evidence: I (Silagy et al 2003).
Comment: Smoking during pregnancy carries a social 
stigma, which may prompt pregnant smokers to deny, 
under-report or minimise smoking. Clinicians must bear 
this in mind when discussing smoking behaviour with 
pregnant women. A good therapeutic relationship, 
based on non-judgmental attitudes on the part of the 
health care worker, and in which trust is established 
with the woman, may facilitate disclosure. 
3.2.4 Supporting smoking cessation
Smokers should be offered support for smoking
cessation and relapse prevention early in pregnancy, and 
as a routine part of each antenatal, child health or clinic
visit. The use of more intensive interventions for smoking
cessation reduces the odds of continued smoking.
Level of evidence: I (Cochrane review: Lumley et al 2001) 
Comment: With all those identified as smokers, ask the 
woman how she feels about her smoking. The type 
of intervention will vary depending on the patient’s 
willingness to quit. 
The three categories of intervention are:
? Current smokers now willing to make a quit attempt 
(cessation support).
? Current smokers unwilling to make a quit attempt 
at this time (motivational intervention).
? Former smokers who have recently quit
(relapse prevention).
Discuss in a collaborative way the options and support 
for quitting smoking; the availability of nicotine
replacement therapy and when it is appropriate;
the risks of passive smoking, especially if her 
partner smokes.
Implementing clinic systems designed to increase the 
assessment and documentation of tobacco use almost 
doubles the rate at which clinicians intervene with
their patients who smoke and results in higher rates of 
smoking cessation.
Level of evidence: I (Miller and Wood 2002)
Comment: Screening; assessment of willingness to 
quit and level of nicotine dependence; and assistance 
provided should be documented in patient records. 
Documentation is particularly important in the antenatal 
setting where the woman may potentially see multiple 
midwives/doctors during her pregnancy. Recording 
screening and smoking cessation interventions therefore 
assists consistency of care delivery and provides 
a prompt for discussion of smoking at numerous visits.
3.2.5 Smoking cessation and mental health
There is some evidence to indicate that nicotine affects 
the metabolism of some antipsychotic medications.
Quitting smoking may therefore contribute to a change 
in mental stability in such a situation. Where a pregnant 
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women who smokes and is prescribed antipsychotic
medications wishes to quit smoking, cessation must 
be undertaken in consultation with the prescribing
psychiatrist, as dose adjustment may be necessary.
Level of evidence: Consensus
At least thirty per cent of people seeking smoking
cessation treatment may have a history of depression.
Depressed people are less likely to quit smoking
successfully than those without a history of depression.
Some may suffer an increase in symptoms after quitting,
however many do not. The period of vulnerability to 
a new depressive episode appears to vary from a few 
weeks to several months after cessation (Miller and 
Wood 2002).
Level of Evidence: Consensus
Comment: Pregnant women with a history of depression 
should be monitored after cessation to assess the 
risks of increased symptoms of depression or a new 
depressive episode, as well as a potential relapse 
to smoking.
3.2.6 Aboriginal and Torres Strait Islander women
Health care workers, in providing interventions and 
pregnancy care, should be aware that tobacco use 
has become the norm in some Aboriginal and Torres 
Strait Islander communities. That is to say, more than 
half of a community may smoke. This constitutes
an additional social barrier to smoking cessation. In 
assisting Aboriginal and Torres Strait Islander women to 
stop smoking, health care providers should support the 
development of achievable goals.
Level of evidence: Consensus
3.2.7 The ‘5 As’
The brief intervention approach to smoking cessation
known as the ‘5 As’ is useful, but is recommended in
these guidelines as the minimum approach to smoking
cessation. Extended psychosocial interventions that 
exceed minimal advice to quit should be made available
for pregnant women, particularly if risk factors such 
as high nicotine dependence, many years smoking,
co-habiting with a smoker, or co-morbid anxiety or 
depression are identified.
Level of evidence: Consensus
1. ASK all women
? ‘Do you smoke tobacco?’ If the answer is ‘no’, ask 
‘Have you ever smoked tobacco’ 
? Record smoking status.
Level of evidence: I (Miller and Wood 2002)
Comment: The second question identifies recent quitters 
(ie they may have quit yesterday and identify themselves 
as non-smokers) who may be at risk of relapse 
throughout pregnancy. Advice may then be given on 
how to stay quit and benefits of remaining quit.
2. ADVISE
? ALL smokers should be advised to quit in a way that 
is clear but non-confrontational (eg ‘The best thing
you can do for your health is to quit smoking.’).
Level of evidence: I (Miller and Wood 2002)
3. ASSESS
? For all smokers, assess stage of change: ‘How do you 
feel about your smoking at the moment?’ and ‘Are 
you ready to quit now?’ 
? Record stage of change. Assess nicotine dependence.
Level of evidence: Consensus in Miller and Wood 2002
4. ASSIST
The assistance provided depends on willingness to quit:
Level of evidence: Consensus in Miller and Wood 2002
? ASSIST (Not ready): 
? Discuss the benefits of quitting and the risks of 
continued smoking.
? Provide information about not exposing others to 
passive smoking.
? Advise that help is available when they’re ready.
? ASSIST (Unsure):
? Do motivational interviewing: ‘What are the 
things you like and don’t like about your smoking?’ 
? Explore their doubts. 
? Explore barriers to quitting.
? Offer written information (eg Quit Kit) and 
referral to Quitline 13 7848 (13 QUIT).
? ASSIST (Ready)
? Affirm and encourage. 
? Provide a Quit Kit and discuss a quit plan. 
? Refer nicotine dependent smokers to a doctor 
to discuss pharmacotherapy. 
? Discuss relapse prevention.
? Offer referral to Quitline 13 7848 (13 QUIT), 
or referral to other available services offering
evidence-based smoking cessation support.
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? ASSIST (Recent quitters)
? Congratulate.
? Discuss relapse prevention.
? Review and reinforce benefits of quitting.
? Offer written information (eg Quit Kit) and 
referral to Quitline 13 7848 (13 QUIT).
5. ARRANGE follow-up 
For women attempting to quit, arrange a follow-up 
visit, if possible.
Level of evidence: Consensus in Miller and Wood 2002
At these visits:
? Congratulate and affirm decision.
? Review progress and problems.
? Encourage continuance of full course of 
pharmacotherapy (if using).
? Discuss relapse prevention.
? Encourage use of support services.
? Refer to general practitioner or to Quitline 13 7848 
(13 QUIT). 
In the antenatal setting, there is also opportunity for 
following up with women who are ‘unsure’ as well as 
those who may be ‘not ready’ to encourage movement 
along the willingness-to-quit spectrum. 
Follow-up visits with their doctor significantly increases 
cessation rates of smokers at six months or more. 
Level of evidence: I (Miller and Wood 2002)
3.2.8 Relapse prevention
Maternal smoking increases the risk of poor health 
outcomes in infants and children, including SIDS, 
respiratory infections, asthma, and middle ear disease,
therefore sustained abstinence in the postpartum period
is even more important than in the general population.
Level of evidence: Consensus (in Fiore et al 2000; 
Miller and Wood 2002)
Comment: Partners of the pregnant woman play an 
important role in successfully quitting smoking. One 
of the predictors of relapse is having a partner who 
continues to smoke.
Providing relapse prevention advice can reduce 
relapse rates. 
Level of evidence: Consensus in Miller and Wood 2002
Because of the chronic relapsing nature of tobacco 
dependence, clinicians should provide brief effective
relapse prevention treatment. When clinicians encounter 
a patient who has quit tobacco use recently, they should:
? Reinforce the patient’s decision to quit.
? Review the benefits of quitting.
? Assist the patient in any residual problems arising
from quitting.
Relapse prevention interventions are especially important
soon after quitting and can be delivered by means 
of scheduled clinic visits, telephone calls, including
referral to the Quitline 13 7848 (13 QUIT), or any time
the clinician encounters an ex-smoker. A systematic,
institutionalised mechanism to identify recent quitters
and contact them is essential to deliver relapse 
prevention messages effectively.
Level of evidence: Consensus in Fiore et al 2000
Women who stop smoking during pregnancy should not 
be regarded as if they have quit smoking permanently. 
Smoking status should be canvassed with the woman at 
each subsequent antenatal visit throughout pregnancy, 
and in the postpartum period. Smoking cessation and 
relapse prevention interventions should be a routine part 
of antenatal and postpartum care.
Level of Evidence: Consensus in British Medical 
Association 2004; Miller and Wood 2002
Comment: About 25 per cent of women quit smoking 
once they become pregnant (USSGR 2004). A quarter 
of these will relapse to smoking during pregnancy. 
Relapse in the postpartum period is high. Relapse 
prevention in the postpartum period is important 
because of the risk of exposure of the infant to 
environmental tobacco smoke. Interventions to prevent 
smoking relapse postpartum have been shown to 
prevent 25 per cent of relapse.
Telephone callback counselling services are effective in
assisting cessation for smokers who are ready to quit.
Repeated telephone support for up to 12 weeks is more 
effective than a single telephone counselling session.
Level of evidence: 1 (Miller and Wood 2002)
Comment: Telephone counselling for smoking cessation 
is very effective and can form the ‘Arrange follow-
up’ section of the ‘5As’ intervention model. In most 
Australian states the Quitline (13 7848 or 13 QUIT) 
provides a free callback counselling service. The calls can 
be tailored to meet the needs of the quitting smoker.
3.2.9 Environmental tobacco smoke
Parents should be advised of the risks associated with
environmental tobacco smoke (ETS).
Level of evidence: Consensus
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Comment: The World Health Organization’s International 
Consultation on Environmental Tobacco Smoke (ETS) 
and Child Health in 1999 brought together experts 
from developed and developing countries to examine 
the effects of ETS on child health and to recommend 
interventions to reduce these harmful effects and 
eliminate children’s exposure. The Consultation 
concluded that ETS is a real and substantial threat to 
child health, causing death and suffering throughout 
the world. ETS exposure causes a wide variety of adverse 
health effects in children, including lower respiratory 
tract infections such as pneumonia and bronchitis, 
coughing and wheezing, worsening of asthma, and 
middle ear disease. Children’s exposure to environmental 
tobacco smoke may also contribute to cardiovascular 
disease in adulthood and to neurobehavioural impairment. 
The Consultation also concluded that maternal smoking 
during pregnancy is a major cause of sudden infant 
death syndrome (SIDS) and other well-documented 
health effects, including reduced birth weight and 
decreased lung function. In addition, the Consultation 
noted that ETS exposure among non-smoking pregnant 
women can cause a decrease in birth weight and that 
infant exposure to ETS contributes to the risk of SIDS 
and SUDI (See section 2.4.3 Sudden Unexpected Deaths 
in Infancy).
It is suggested that screening questions be used for 
pregnant women and new parents regarding potential
for exposure to ETS. This may include asking whether 
there are smokers living in the home, and advising that, 
to reduce ETS, partners, family and friends do not smoke 
in the home or the car, or ideally, become non-smokers.
Level of evidence: Consensus
3.2.10 Nicotine replacement therapy (NRT) 
in pregnancy
There is currently a lack of evidence on the safety of 
NRT in pregnancy but reports of expert committees
have recommended its use in certain circumstances. 
NRT should be considered when a pregnant woman is
otherwise unable to quit, and when the likelihood and 
benefits of cessation outweigh the risks of NRT and 
potential continued smoking.
Level of Evidence: Consensus in Fiore et al 2000
Comment: NRT can have a substantial impact on 
the chances that a dependent smoker will be able to 
quit, but there is concern that its use in pregnancy 
may have adverse effects on the fetus. The safety 
and efficacy in pregnancy of pharmacotherapies such 
as NRT and bupropion is still debated and further 
research is required. The ratio of potential benefit to 
harm is uncertain, so most recommendations are to 
consider pharmacotherapy only after psychosocial 
intervention has failed (such as cognitive behavioural 
therapy, counselling, group support). Pregnant women 
in Australia are not prohibited from using NRT, but it is 
classified as a Category D product during pregnancy, and 
it is recommended that medical advice be sought before 
use. (See Appendix 7: Categorisation of drug risks in 
pregnancy and breastfeeding.) In Australia NRT packages 
carry warnings against its use in pregnancy, but the 
Australian Therapeutic Goods Administration notes that 
‘Short term exposure during the first trimester is unlikely 
to cause a hazard to the fetus’2.  
The pregnant woman should be advised to discuss the 
use of NRT with her doctor as soon as it appears that 
she will be unable to quit using non-pharmacological
interventions alone. 
Level of Evidence: Consensus
Comment: The woman’s general practitioner should 
support NRT after two or more weeks of the woman 
trying to quit without success.
The goal in pregnancy should be to be free of both 
tobacco and nicotine. Nicotine itself has been shown 
to be toxic to the developing fetus in animal studies.
While NRT products are not completely without risk,
the dose of nicotine is smaller and the risk to the fetus 
is much lower than that associated with continuing to 
smoke. Tobacco smoke contains carbon-monoxide and 
more than four thousand other chemicals, many of 
which are also reproductive toxins. NRT does not contain
these other chemicals. If NRT use is recommended after 
consultation with the treating doctor, intermittent-use
formulations (gum, lozenge, inhaler, sublingual tablet) 
are preferred for use during pregnancy because they 
provide smaller daily doses of nicotine than continuous-
use formulations (transdermal patches). 
Level of Evidence: III-2 (Dempsey and Benowitz 2001)
If the clinician and the pregnant woman decide to use 
NRT, the clinician should consider:
? monitoring blood nicotine levels to assess the level of 
drug delivery
? using medication doses that are at the low end of 
the effective dose range (but see below)
2 Therapeutic Goods Administration, Australian Drug Evaluation
Committee, 1999. Prescribing medicines in pregnancy: an Australian 
categorisation of risk of drug use in pregnancy, 4th edition. Australian
Department of Health and Ageing, p. 52.
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? choosing delivery systems that yield intermittent,
rather than continuous, drug exposure (eg gum 
rather than patch). 
Level of Evidence: Consensus in Fiore et al 2000
The total time to completion of NRT should be 
monitored and should not exceed the recommended 
regimen. Some clinicians and women may find blood 
tests a barrier and may prefer to monitor urine
cotinine levels.
Effective dose range: There is some evidence that 
nicotine and cotinine metabolism is accelerated in
pregnancy, which means that the effective dose range 
may be higher in pregnancy than it is for non-pregnant 
women. A woman continuing NRT from before 
pregnancy may not be effectively treated with a reduced 
dose, or may even require an increased dose.
Level of Evidence: IV (Dempsey et al 2002)
Comment: The total dose of nicotine delivered to fetus 
is less with intermittent than with continuous-use 
formulations of NRT. Cigarette smoking does not deliver 
nicotine continuously, so the effects on the fetus of 
continuous exposure to nicotine are unknown. NRT 
should be discontinued early in pregnancy once cessation 
is achieved. Women who have quit during pregnancy 
should be monitored to ensure that relapse doesn’t occur.
3.2.11 Bupropion and smoking cessation
The use of bupropion during pregnancy or lactation
is listed as a precaution in MIMS (2005) and is
not recommended.
Level of evidence: Consensus
Comment: Bupropion is an effective non-nicotine 
medication that is available only on prescription. It 
may not be appropriate for all smokers. Bupropion 
can be combined with NRT to help with quitting. The 
medication is commenced approximately one week 
prior to quitting and reduces the urge to smoke, but 
should be combined with counselling. At the time 
of publication Zyban is the only form of bupropion 
available in Australia.
3.2.12 Myths to be discounted in informing 
women of the risks
The idea that nicotine withdrawal during smoking
cessation is more stressful to the fetus than continued
smoking is not supported by evidence, and should not 
be given as advice.
Level of Evidence: Consensus in British Medical Association 
2004; US Surgeon General’s Reports, 2001 and 2004
Comment: The evidence for the large range of negative 
health effects caused by smoking in pregnancy is vast. 
Among other harmful effects, women who smoke 
in pregnancy are three times more likely to have a 
baby with low birthweight for gestational age. Low 
birthweight babies are at increased risk of illness, 
death in infancy and health consequences in later life. 
The physiological effects of smoking on fetal growth 
are caused by reduced oxygenation of blood to the 
fetus. This occurs primarily through two independent 
mechanisms: first the vasoconstrictive effects of 
nicotine on the uterine and umbilical arteries; second 
the increase in carboxyhemoglobin, the concentration 
of carbon monoxide in the blood, with higher carbon 
monoxide concentration in fetal than in maternal blood. 
These two factors combined produce a reduction in fetal 
blood flow, increasing the risk of low birth weight for 
gestational age. In addition, cigarette smoke contains 
more than 4000 other toxins, including mutagens and 
carcinogens, which are conveyed to the fetus in the 
blood. Studies show an increased risk of SUDI among 
offspring of women who smoke during pregnancy.
Level of Evidence: Consensus in British Medical Association 
2004; US Surgeon General’s Reports, 2001 and 2004
In the case of tobacco smoking, the practice of ‘cutting
down’ (sometimes described as ‘harm reduction’) on 
the number or strength of cigarettes smoked is not 
supported by evidence that it provides any protection
to the fetus and is not recommended. Women should 
be informed of this and complete abstinence from 
smoking should be recommended as best for the mother 
and fetus.
Level of evidence: Consensus
Comment: This may seem counter-intuitive to some 
people, but there is no evidence that cutting down the 
number of cigarettes smoked leads to a reduction in 
serum nicotine levels. Evidence suggests that smokers 
titrate their nicotine intake by varying their inhalation 
habits. Stronger inhalations lead to greater exposure to 
the harmful impact of carbon monoxide. If a woman 
reports a change in smoking either through reduction 
in number or reduction in strength of cigarettes asking 
about how she inhales the smoke may provide an 
indication of compensatory smoking. 
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3.3.1 Heroin
A heroin-dependent pregnant woman should be offered 
stabilisation through induction onto a methadone 
program, combined with drug and alcohol counselling
and psychosocial support. 
Level of evidence: Consensus
Comment: See also to section 2.2.18, Late presentations 
and section 2.3.3, Out of hours emergency presentations.
3.3.2 Contraceptive advice and 
pregnancy planning
When opioid-dependent women are admitted to 
an opioid treatment program (on methadone or 
buprenorphine maintenance), their health and therefore 
their fertility is likely to improve. This may increase the 
risk of unplanned pregnancy. This possibility should be 
discussed with women entering treatment, who need 
advice about reliable and easy to use methods 
of contraception.
Level of evidence: Consensus
3.3 Opioids
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Note: Methadone is always given in liquid form for the 
treatment of addictive disorders.
3.4.1 Efficacy of methadone 
maintenance treatment
Observational studies have found that heroin use 
in pregnancy is associated with intrauterine growth 
restriction (IUGR). Methadone maintenance treatment 
(MMT) is associated with improved fetal development 
and infant birth weight. This effect is reduced by 
continued use of heroin during pregnancy. 
Level of evidence: III 2 
MMT throughout pregnancy reduces the risk of perinatal
and infant mortality in heroin-dependent women. 
Continued heroin use in pregnancy may reduce this
protective effect. 
Level of evidence: III 2 
Methadone treatment during pregnancy is not 
associated with adverse postnatal development in
children of opioid-dependent women. 
Level of evidence: III-2
3.4.2 Methadone induction
Heroin-dependent pregnant women should have priority
access to methadone treatment. This may include
admission to an inpatient obstetric unit for stabilisation
and rapid dose titration, with respite from the 
external environment. 
Level of evidence: Consensus
Partners of pregnant women who are using heroin
should also be offered priority access to opioid
substitution treatment. 
Level of evidence: Consensus
Comment: A partner’s use of heroin increases the 
woman’s risk of relapsing into heroin use.
3.4.3 Adequate dosing
The methadone dose during pregnancy should be 
titrated to a level that not only blocks withdrawal
symptoms, but also suppresses heroin use. 
Level of evidence: Consensus 
Comment: Methadone dose should be titrated 
according to the woman’s symptoms and not kept low 
in an attempt to reduce neonatal abstinence syndrome 
(see section 3.4.4, Relationship between methadone 
dose and neonatal abstinence syndrome).
During pregnancy, methadone dose increases may be 
required due to increased metabolism and increased 
blood volume. 
Level of evidence: Consensus
3.4.4 Relationship between methadone dose 
and neonatal abstinence syndrome
Multiple factors contribute to the severity of NAS in
children born to opioid-dependent women including
(but not limited to) maternal smoking, heroin use, and 
benzodiazepine dependence. There is no clear dose–
response relationship between methadone and risk
of NAS. 
Level of evidence: III-3 
Comment: It is not possible to confidently predict risk of 
NAS based on maternal dosage, as there are many other 
factors that influence NAS outcomes, such as maternal 
polydrug use, type of opioid used and gestational age 
at birth. While there is some data that suggest infants 
exposed to higher methadone doses in utero may be 
at increased risk of NAS, this is only one small factor in 
a complex equation.
3.4.5 Detoxification from opioids
Methadone
Withdrawal from methadone is associated with a 
high risk of relapse to heroin use and should not be 
encouraged during pregnancy. 
Level of evidence: IV 
Heroin
A pregnant woman seeking withdrawal from heroin
as an intervention during pregnancy (ie supervised
detoxification) should be informed of the risks and 
benefits, including the risks to the fetus (increased 
risk of infant mortality and low birth weight for 
gestational age) and the high risk of relapse. Methadone 
maintenance treatment should be offered in the 
first instance. If the woman still refuses methadone 
maintenance treatment, then the risks of supervised
withdrawal may be reduced by undertaking withdrawal
under the following conditions:
? in the second trimester only, that is during weeks 
14 to 32
3.4 Methadone
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? with fetal monitoring, in a monitored setting, such 
as an inpatient obstetric unit
? using tapering doses of methadone to create 
a gradual withdrawal.
During this period, the benefits of methadone 
maintenance should be continually discussed.
Level of evidence: Consensus
3.4.6 Split dosing
There is insufficient evidence to say whether split dosing
with methadone is preferable to single daily dosing
during pregnancy. It may help stabilise conditions within
the uterus for the developing infant by reducing the 
difference between peak and trough concentrations of 
methadone in the blood. It is recommended that split
dosing be available as a clinical option for all pregnant 
women who experience withdrawal symptoms as 
pregnancy advances. Systematic research into the effects 
of split dosing should be undertaken. 
Level of evidence: Consensus 
Each State and Territory jurisdiction should develop 
policy guidelines that allow for split dosing when there 
is a clinical need. The guidelines should allow the 
second part of the dose to be provided as a takeaway, 
provided the usual safety criteria for takeaways can 
be met. This will avoid requiring the woman to attend 
the clinic twice daily. Issues to be taken into account 
in issuing a takeaway dose include (but are not limited
to): the opening hours of the clinic, the distance and 
cost of transport, the presence of other children in the 
household, the presence or absence of a reliable partner 
to share the care of the other children, the woman’s 
involvement in paid work.
Level of evidence: Consensus 
3.4.7 Management of vomiting in pregnant 
women on MMT
Vomiting is a serious concern in pregnant women on 
methadone maintenance. Vomiting of a methadone 
dose may lead to withdrawal in both mother and fetus. 
Withdrawal symptoms cause fetal distress, and should 
be avoided. Services should develop protocols to guide
staff in the event that a pregnant woman vomits after 
her methadone dose. If there is no protocol, then the 
prescriber should be notified.
If a methadone dose is vomited by a pregnant woman
? within 10 minutes of dosing – consider giving a 
repeat dose
? within 10–60 minutes of dosing – consider giving
half a repeat dose
? more than 60 minutes after dosing – consider giving
half a repeat dose if withdrawal occurs.
It is preferable that staff have observed the vomiting, but 
since it is unlikely that all stomach contents are expelled 
during a vomit, it is still difficult to be sure how much of 
the dose can be absorbed. Where there is doubt, every 
effort should be made for the woman to be reassessed 
by an experienced clinician 4 to 6 hours after vomiting,
when the effects of methadone should be at their
peak, to determine whether an additional small dose 
is required. 
The following points are recommended for managing
ongoing problems with vomiting during pregnancy:
? Women should be discouraged from ingesting
methadone on an empty stomach.
? Women should be encouraged to sip their
dose slowly.
? If the dose of methadone appears to consistently
cause vomiting, consider splitting the dose or giving
rectal prochlorperazine 30–60 minutes before dosing.
? If a woman vomits constantly and not necessarily in
relation to her dose of methadone, she should be 
assessed and treated according to obstetric protocols 
for hyperemesis gravidarum:
? Assess degree of dehydration and ketosis
(Consider admission if urine ketones are 
more than 2+).
? Look for other causes of vomiting (eg urinary
tract infection).
? Consider need for intravenous rehydration.
? Consider need for pharmacotherapy (eg rectal 
prochlorperazine, or intramuscular or intravenous
ondansetron). 
? Consider need for improving nutritional status 
(eg improved diet, vitamin/iron supplements).
Level of evidence: Consensus 
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3.4.8 Dose review after giving birth
Dose reduction after giving birth is currently a common 
practice, but the extent and timing of dose reductions
has not been investigated in research studies. The 
maintenance dose should be reviewed in the early days 
following birth, and regularly as indicated thereafter. 
The focus in reviewing the dose should be on 
supporting and enhancing the woman’s stability, 
taking into account: 
? signs of withdrawal or intoxication
? assessed risk of reverting to illicit drug use. 
Effective liaison between the midwife, obstetric services,
neonatal services, child protection services, Aboriginal
medical services and drug treatment services is crucial in
the postnatal period. It can be facilitated by the 
case manager (regardless of where the case manager 
is located).
Level of evidence: Consensus 
Breastfeeding
Refer to section 2.5, Breastfeeding.
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3.5.1 Women already on buprenorphine 
maintenance treatment
The appropriate first line treatment for an opioid-
dependent woman who is pregnant, or who plans 
to become pregnant, is methadone maintenance
treatment. However, if a woman is already on 
buprenorphine maintenance treatment (BMT), wishes
to continue, and can provide informed consent, it is
acceptable to continue buprenorphine maintenance
during pregnancy and breastfeeding. For further 
guidance, refer to the Revised National Clinical 
Guidelines and Procedures for the use of Buprenorphine 
in the Treatment of Heroin Dependence
www.nationaldrugstrategy.gov.au/publications/illicit.htm.
Level of evidence: Consensus
Extended follow-up of infants exposed to buprenorphine
in utero is strongly recommended, for example, a full 
developmental paediatric assessment at 2 years of age.
Level of evidence: Consensus 
Comment: Informed consent is a critical and complex 
issue for women who are pregnant, and particularly 
so for treatments where limited data are available on 
safety (such as buprenorphine and naltrexone). However, 
it is likely that the risks of ongoing heroin use greatly 
outweigh the risks of buprenorphine maintenance. It 
is preferable that women already on buprenorphine 
continue that treatment rather than run a risk of 
relapsing into heroin use. Not all pregnant women 
already on buprenorphine will transfer to methadone. 
It is not feasible to enrol all pregnant women on 
buprenorphine in clinical trials — currently only one 
Australian State is holding a clinical trial. Informed 
consent to treatment and long-term follow-up of 
the infant are crucial. 
3.5.2 Induction onto buprenorphine from heroin 
during pregnancy
Sometimes heroin-dependent pregnant women 
present for treatment, will not accept methadone 
and request buprenorphine. Unlike methadone, the 
safety of buprenorphine in pregnancy has not been 
demonstrated, and will not be for at least several years. 
Nonetheless, treatment guidelines should not restrict
specialist obstetric units and drug and alcohol specialists
from using buprenorphine as a treatment for heroin-
dependent pregnant women who refuse methadone 
treatment and can provide informed consent. 
Level of evidence: Consensus 
Comment: Induction into buprenorphine maintenance 
treatment during pregnancy should not be considered 
a routine option, nor should it be undertaken without 
specialist obstetric and addiction advice and support, 
preferably by referral to a specialist unit. Access to 
clinical trials is limited, but, if possible, the woman 
should be offered enrolment in a trial.
Breastfeeding
Refer to section 2.5, Breastfeeding.
3.5.3 Transfer of pregnant women from 
MMT to BMT
Transfer of a pregnant woman already on methadone 
maintenance treatment to buprenorphine maintenance
treatment is strongly advised against, because of the 
risks of precipitated withdrawal.
Level of evidence: Consensus 
Comment: Buprenorphine is a partial opioid-receptor 
agonist with a higher affinity for opioid receptors than 
methadone. If a person stabilised on methadone takes 
a dose of buprenorphine, the effect can be similar to 
taking an opioid antagonist: precipitated withdrawal.
3.5 Buprenorphine
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The safety and efficacy of naltrexone in pregnancy is
not established. Human studies regarding the effects 
of naltrexone in pregnancy are very limited. Naltrexone 
should not be offered in pregnancy, except in the 
context of clinical trials.
Level of evidence: Consensus 
If a woman on naltrexone becomes pregnant, and is
progressing well in treatment, she should be advised
that the safety of naltrexone is not established. If she 
wishes to continue naltrexone and can provide informed
consent, it is acceptable to continue naltrexone during
pregnancy. Follow-up of babies exposed to naltrexone 
in utero is recommended, such as a comprehensive
developmental assessment by a paediatrician at 2 years 
of age.
Level of evidence: Consensus 
3.6 Naltrexone
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3.7.1 Risks
The health risks of cannabis in pregnancy have not been 
clearly established. For the woman they may include
increased risk of respiratory problems, mood and other 
psychological problems, and financial and other 
social problems.
Cannabis is often taken mixed with tobacco, and 
the harms associated with tobacco in pregnancy 
are considerable.
There is no evidence of neonatal abstinence syndrome 
solely from cannabis use. There is low level evidence
of a mild withdrawal from sole cannabis use. This is
not usually apparent until at least the second week 
postnatally. It is unlikely to require care in the neonatal 
nursery or separation from the mother. It is important
parents are taught supportive settling techniques. Refer 
to section 4.7, Supportive therapies for babies at risk
of NAS. 
Mothers should be advised that regular exposure 
to cannabis in utero may influence newborn infant
behaviours in the first weeks of life.
Level of Evidence: Consensus
Pregnant women should be advised that while the 
health risks of cannabis in pregnancy have not been 
clearly established, some studies have suggested that 
children born to cannabis-dependent parents may have 
some developmental problems, such as:
? subtle differences in higher cognitive processes and 
perceptual organisation (but less than those due to 
nicotine or other substances used in pregnancy)
? sleep disturbances in 3-year-olds
? reduced memory and performance on verbal scales 
at 3 years
? reduced height at 6 years
? increased child hyperactivity, impulsivity and 
inattention at 10 years.
Level of Evidence: III-2
Comment: While there have been case reports of 
increased risk associated with in-utero cannabis 
exposure, current evidence does not indicate it is 
a teratogen.
Screening
Refer to section 2.2.5, Screening.
3.7.2 Management
Pregnant women should be advised of the possible
physical, psychological and social implications for 
themselves and their infant from regular cannabis use. 
Level of Evidence: Consensus
If a pregnant woman identifies herself as a regular 
cannabis user, she should be offered a range of 
interventions to help her stop, including information,
brief intervention, counselling and psychologically based 
treatment for cannabis dependency.
Level of Evidence: II
Comment: The primary management of pregnant 
women using cannabis is counselling. There is some 
evidence of psychiatric disorders associated with 
cannabis dependence.
Safe sleeping 
Refer to section 2.4.3, Sudden unexpected deaths in
infancy (SUDI).
Breastfeeding
Refer to section 2.5.8, Breastfeeding and cannabis.
3.7 Cannabis
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3.8.1 Risks
The health risks of benzodiazepines in pregnancy 
have not been clearly established. There have been 
inconsistent reports of morphological problems 
associated with fetal exposure to benzodiazepines.
Regular benzodiazepine use in pregnancy may be 
associated with a neonatal abstinence syndrome, which
may be of delayed onset. 
Intoxication with any drug while caring for a young child
is risky, and pregnant women should be informed of 
universal SIDS precautions and safe sleeping practices.
Screening
Refer to section 2.2.5, Screening.
3.8.2 Management
Ideally, the recommended management of a 
benzodiazepine-dependent pregnant woman is transfer 
to a long-acting benzodiazepine (diazepam) and gradual 
dose reduction, with a view to being drug-free at birth.
While this is the ideal goal of treatment, clinicians must 
work individually with each woman to set goals that are 
achievable for her.
Level of evidence: Consensus
Babies born to benzodiazepine-dependent women 
should be observed for 1 week in hospital before 
discharge, and should have an outpatient review
weekly during the first month of life. The Finnegan
scale may be used to identify neonatal abstinence
syndrome associated with benzodiazepines (see section
4.4, Measuring NAS caused by other drugs, including
polydrug use). Educating parents to watch for signs
of withdrawal after discharge may be helpful, with
instructions to present earlier if indicated by the 
infant’s behaviour. 
Supportive measures without drug treatment 
are the primary management of the baby, but 
if pharmacological treatment of benzodiazepine
withdrawal is required, phenobarbitone is the drug 
of choice. Refer to section 4.11.2, Treatment of 
non-opioid withdrawal.
Level of evidence: IV
Safe sleeping 
Refer to section 2.4.3, Sudden unexpected deaths in
infancy (SUDI).
Breastfeeding
Refer to Section 2.5.6, Breastfeeding and 
Benzodiazepines.
3.8 Benzodiazepines
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3.9.1 Risks
The health risks of amphetamine use in pregnancy 
have not been clearly established. There have been 
inconsistent reports of problems associated with
exposure in utero, including the development of cerebral 
ischemic lesions. It has been suggested that a history of 
amphetamine use, particularly intravenous amphetamine
use, should be taken as a marker of 
a high-risk pregnancy. 
There are few reports of neonatal abstinence symptoms 
associated with maternal amphetamine use. In one 
study of 134 infants exposed to amphetamines in utero, 
49 per cent experienced withdrawal symptoms, but only 
4 per cent required medication.
If amphetamines are used close to the birth, the baby 
may be born directly affected, and may be over-active
and agitated. Refer to Part 4, Management of neonatal 
abstinence syndrome (NAS), as the symptoms are similar.
Screening
Refer to section 2.2.5, Screening.
3.9.2 Management
A pregnant woman using amphetamines should be 
advised of the potential health risks to herself and to 
her baby. Women seeking further support should be 
provided with counselling. Care should be provided
within a multidisciplinary framework. Women should be 
encouraged to reduce or cease amphetamine use. Use 
of amphetamines is associated with mental illness and 
mental health should be monitored.
Level of evidence: Consensus
Breastfeeding
Refer to section 2.5.7, Breastfeeding and 
psychostimulants.
3.9 Amphetamines
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3.10.1 Risks
Cocaine use during pregnancy has been associated with
an increased risk of intra-uterine growth restriction,
placental abruption and premature rupture of 
membranes. Many effects thought to be attributable
to cocaine, however, could be explained by concurrent 
tobacco use, cannabis use or the quality of the 
environment. The evidence is inconsistent. Nevertheless, 
a history of cocaine use, particularly intravenous use, 
should be taken as a marker of a high-risk pregnancy. 
Level of evidence: Consensus.
Neonatal withdrawal symptoms from cocaine are 
seen much less frequently than symptoms of opioid
withdrawal. Neonatal withdrawal from cocaine may be 
mild and not require medication. Refer to section 4.11.2, 
Treatment of non-opioid withdrawal.
Developmental problems have been observed in
children exposed to cocaine in utero, although whether 
this is a result of in-utero exposure, or a result of 
environmental factors, is unclear. Children with identified
developmental and cognitive problems following in-
utero exposure respond to early intervention and other 
educational interventions.
Screening
Refer to section 2.2.5, Screening.
3.10.2 Management
A pregnant woman using cocaine should be advised
of the potential health risks to herself and to her baby. 
Women seeking further support should be provided
with counselling.
Level of evidence: Consensus
Breastfeeding
Refer to section 2.5.7, Breastfeeding and 
psychostimulants.
3.10 Cocaine
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3.11.1 Risks
Inhalant use is an increasing concern in Australian
society, particularly in some rural and remote 
communities. Few data have been collected regarding
the prevalence of inhalant use nationally, or about best 
management strategies.
There is evidence to suggest that inhalant use is
associated in the long term with central nervous system 
damage, which results in tremors when attempting
to move, poor coordination and difficulty walking.
Personality may also be affected resulting in volatile
mood swings.
During pregnancy, inhalant use is associated with low 
birth weight for gestational age and increased risk of 
miscarriage, birth defects and SIDS.
An abstinence syndrome has been observed in infants
born to mothers known to be volatile substance users 
during their pregnancy. This consisted of a characteristic
odour (reflecting pulmonary excretion of the volatile
substance), excessive and high-pitched cry, sleeplessness, 
hyperactive Moro reflex, tremor, hypotonia and 
poor feeding.
Level of evidence: IV
Screening
Refer to section 2.2.5, Screening.
3.11.2 Management 
In Aboriginal and Torres Strait Islander communities,
clinical interventions should always be guided by the 
principles identified by the Ministerial Council on Drugs 
Strategy (2003–2006) for addressing substance use for 
Aboriginal and Torres Strait Islander peoples, listed in
section 2.1, Aboriginal and Torres Strait Islander women.
3.11 Inhalants
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4.1 Definition of NAS
Neonatal abstinence syndrome (NAS) is a syndrome 
of drug withdrawal observed in infants of mothers 
physically dependent on drugs, manifested by non-
specific symptoms and signs in the infant. NAS is more 
common in infants born to opioid-dependent women 
than in infants born to women dependent on other 
drugs or alcohol. NAS in infants of opioid dependent 
mothers is manifested by neurological excitability, 
gastrointestinal dysfunction and autonomic signs.
There may be poor feeding, sleep-wake abnormalities,
vomiting, dehydration, poor weight gain and 
occasionally seizures. 
Relationship between NAS and antenatal care
The outcomes of infants at risk of NAS depend in part 
on the quality of antenatal care the woman receives
during pregnancy. In particular:
? Assessment and preparation of a care plan as part 
of the coordinated antenatal management of the 
pregnant woman and her family has an important
positive impact on neonatal outcomes.
? Late presentations in pregnancy are associated
with inadequate antenatal care, which can have a 
negative impact on the neonate. 
For a guide to management of a drug-dependent 
pregnant woman, see section 2.2, Antenatal care.
Concurrent illness
Concurrent illness, including infection and 
hypoglycaemia, should be considered when assessing an 
infant at risk of NAS. 
Level of evidence: Consensus. 
Comment: Infants of mothers with a drug or alcohol 
problem are at increased risk of preterm birth 
and low birth weight, frequently associated with 
chorioamnionitis. Clinical signs of illness such as infection 
and hypoglycaemia may overlap with those of NAS. 
4.2 Detecting NAS
Infants of all mothers taking opioids for a prolonged 
period during pregnancy should be monitored for NAS. 
Level of evidence: III-2
Comment: Withdrawal in the neonate has been 
documented even if methadone was stopped one 
month earlier (but not more), so it is important that 
an accurate maternal history of opioid use is taken. 
On the other hand, the babies of women receiving one 
dose of opioid, for example, during birth, should not 
be considered at risk of withdrawal.
4.3 Measuring opioid NAS
A validated assessment tool for determining which
infants have NAS should be used. 
Level of evidence: III-2. (Lipsitz 1975; Finnegan et al 1975;
O’Brien et al 2004; Zahorodny et al 1998; Osborn et al 2005a). 
The recommended assessment tools in these guidelines
are the Finnegan neonatal abstinence severity score 
(NASS) or the modified Finnegan neonatal abstinence
severity score (see Appendix 10: Examples of neonatal 
abstinence syndrome scoring scales). 
Level of evidence: Consensus
Comment: Other validated assessment tools have 
also been used, such as the Lipsitz and the neonatal 
withdrawal scale (NWS), but the Finnegan tools are 
recommended here because they are already taught as 
a standard across Australia. (see sections 3.1.5, Neonates 
and infants; 3.7, Cannabis; 3.8; Benzodiazepines; 3.9, 
Amphetamines; 3.10, Cocaine)
4Management of neonatal abstinence 
syndrome (NAS)
PAGE 46  National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn
4.4 Measuring other NAS
The Finnegan or modified Finnegan scale should 
also be used 
1. to assess withdrawal from other drugs, including
benzodiazepines and alcohol
2. to assess possible stimulant intoxication in the 
neonatal period, if perinatal history indicates that this
is appropriate.
Level of evidence: Consensus
Comment: Although the Finnegan scale is not 
adequately validated for use in this situation, sedative 
withdrawal and stimulant intoxication share many of 
the same neurological features as opioid withdrawal, 
including risk of seizures. (see sections 4.5 Monitoring of 
newborns
4.5 Monitoring of newborns
All babies born to drug-dependent mothers should 
receive routine postnatal monitoring, plus specific
assessment with the Finnegan or modified Finnegan
scale, commencing 2 hours after birth and subsequently 
every 4 hours. 
Level of evidence: Consensus
Comment: The Finnegan scale is usually scored every 
4 hours (30–60 minutes after feeds). The score is an 
important guide to proper management of NAS (see 
section 4.10, Initiating pharmacological treatment of NAS).
4.6 Resuscitating the baby of 
a opioid-using mother
If there is a history of regular opioid use during
pregnancy, use of antagonist agents such as naloxone 
(and naltrexone) in the neonatal period, including for 
resuscitation, is contraindicated. Its use may precipitate
severe rapid onset of withdrawal associated
with seizures. 
In the event of respiratory depression in an infant of an 
opioid-dependent mother, normal resuscitation methods 
should be used (without naloxone), including thorough 
assessment and mechanical ventilation as required. 
Level of evidence: Consensus
4.7 Supportive therapies for babies
Non-pharmacological management is the first line
of treatment for all babies born to drug-dependent 
women. That management will include supportive care 
interventions, such as a quiet setting, breastfeeding,
use of a pacifier, cuddling, swaddling, small frequent 
feeds, and close skin contact by carrying in a sling and 
other methods. Close monitoring of weight loss during
the period of withdrawal is necessary because feeding
disturbances are common. Where caloric intake appears 
insufficient with breastfeeding alone, consideration
should be given to the use of supplemental expressed 
breast milk or formula until adequate caloric intake
is established.
Level of evidence: Consensus
Comment: Breastfeeding is an important aspect of 
care (see section 2.5, Breastfeeding). Decisions about 
the safety of breastfeeding should consider all the 
drugs being used by the mother, including alcohol and 
prescribed drugs. 
Despite the importance of non-pharmacological
therapies for babies with NAS, treatment with supportive
care and morphine is more effective than supportive care 
alone, significantly reducing time to regain birth weight
and the duration of supportive care.
Level of evidence: III-1
4.8 Role of parent/s
If the mother and father demonstrate interest and ability, 
they should be involved in the assessing and managing
of NAS. With this in mind, parents should be informed
and educated during the antenatal period about the 
risks, supportive care, assessments and treatments of NAS.
Level of evidence: Consensus
Comment: See Appendix 11: Example of parent 
information brochure on NAS.
4.9 Support for mothers/parents
Mothers of infants at risk of NAS should receive
appropriate breastfeeding information and support, 
parenting support and assessment, and should be 
taught settling techniques. Women and their partners/
support persons should also receive information about 
safe sleeping practices, especially while using sedating
medications, including methadone.
Level of evidence: Consensus
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4.10 Initiating pharmacological 
treatment
Pharmacological treatment of infants with NAS due 
to opioids should be initiated when the Finnegan or 
modified Finnegan score averages 8 or more on 3 
consecutive scores or 12 or more on 2 consecutive
scores when assessed by an experienced scorer.
Level of evidence: III-1 (Osborn et al 2005a and 2005b)
4.11 Pharmacological choices of 
treatment
4.11.1 Treatment of opioid withdrawal
Use of opioids for infants with NAS 
due to opioid withdrawal
An opioid should be used as initial treatment for infants
with NAS symptoms due to opioid withdrawal. The 
opioid of choice is morphine.
Level of evidence: III-1 (Osborn et al 2005a)
Comment: Opioids should not be used unless 
there is confidence that the NAS is induced by 
opioid withdrawal. 
It is unclear from the evidence what the starting dose 
of opioid should be. Tempered by the use of clinical
judgement, a starting dose of morphine 0.5 m/kg/day in
four divided doses (six-hourly) is recommended. Doses 
should be titrated to NAS scores, that is, to control 
infant signs of NAS. 
Level of evidence: III-1 (Osborn et al 2005a)
Comment: Infants with opioid-related NAS are less likely 
to have seizures if treated with an opioid. They are also 
less likely to require treatment with a second agent, and 
may have a reduced duration of treatment.
Use of phenobarbitone for infants with NAS due to 
opioid withdrawal
The benefits of using phenobarbitone in addition to an 
opioid for infants with opioid-related NAS are unclear. 
If there has been concurrent use of other drugs in
pregnancy, particularly benzodiazepines, and symptoms 
of NAS are not adequately suppressed by an opioid
alone, phenobarbitone may be indicated as an 
additional therapy. 
Level of evidence: III-1 (Osborn et al 2005a)
4.11.2 Treatment of non-opioid withdrawal 
Infants with NAS due to unknown drug use 
or drug use not including opioids
If an infant has signs of NAS and the drugs used by 
the mother are unknown, an experienced person 
should make a full assessment of maternal drug use. 
In addition, infant urine and meconium may be used 
for toxicological analysis.
Level of evidence: Consensus 
If an infant has signs of NAS and reaches the treatment 
threshold (see section 4.10, Initiating pharmacological
treatment of NAS), and the drugs used by the mother 
are unknown, or are sedatives, such as benzodiazepines,
or the infant was born to a mother intoxicated with
alcohol, then phenobarbitone should be used as 
initial treatment.
Level of evidence: Consensus
Comment: It is rare for infants to require 
pharmacological treatment for NAS due to other drugs 
including tobacco, cannabis, amphetamines, cocaine 
or antidepressants.
Dosing with phenobarbitone
It is unclear whether a loading dose of phenobarbitone
should be used. If used as initial therapy (rather than in
addition to an opioid), then a loading dose is likely to 
achieve more rapid control of symptoms.
Level of evidence: III-1 (Osborn et al 2005b)
Phenobarbitone should be commenced at a dose of 
5 mg/kg/day split into two divided doses. The dose 
should be titrated to achieve control of NAS according
to the Finnegan score.
Level of evidence: III-1 (Osborn et al 2005b)
4.12 Setting for care of baby
Whether the infant being assessed or treated for NAS is
cared for in a special care nursery or with the mother on 
the postnatal ward varies across Australia. In principle,
unnecessary separation of the infant from the mother 
should be avoided. However, the safety of the infant
is the primary concern. Setting for care will depend 
on individual circumstances, the health care facilities
available, the condition of the baby and the ability of 
the mother to safely care for the baby. 
Level of evidence: Consensus
Comment: Wherever possible, the first choice should be 
to keep the infant with the mother. 
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4.13 Drug testing of newborn, 
Day 1
Routine urine drug testing of all infants is not indicated.
Urine drug testing and/or meconium drug testing may 
be performed where it is considered of diagnostic
importance to work out what drugs the mother has 
been using, particularly where there is no confident
therapeutic relationship with the mother. In cases where 
it is decided to undertake urine or meconium testing,
then the test should be explained to the mother, and 
informed consent should be obtained.
Level of evidence: Consensus
Comment: The quality of the therapeutic relationship 
is an important factor in obtaining reliable information 
from the mother.
4.14 Minimum length of stay 
of baby
Infants at risk of NAS should remain in hospital for at 
least 5 days. This allows for a minimum time to monitor
for signs of NAS, assess the parents’ parenting skills,
assess the adequacy of infant feeding and check for 
excessive weight loss. 
Level of evidence: Consensus
Comment: This recommendation is not meant to 
discourage longer hospital stays for the baby at risk 
of NAS. Some infants have a delayed onset of NAS, 
requiring a longer stay in hospital. (see Appendix 12: 
Duration of postnatal hospitalisation required to detect 
severe NAS).
4.15 Safe discharge
4.15.1 Criteria for safe discharge of infants home
All mothers should be assessed adequately before 
discharge with respect to current drug usage and 
psychological stability, parent craft abilities, and social
situation. The infant’s well-being must also be assessed. 
Absolute contraindications to discharge home include:
? excessive weight loss (10 per cent or more of 
birth weight)
? baby not yet 5 days old
? suspected infant neglect or abuse
? suspected home violence
? a court order preventing baby from being
discharged home
? further assessment for withdrawal is required. 
Relative contraindications to discharge home include:
? poor parent craft ability of mother or primary carer
? inadequate home support or acceptance 
of assistance
? inadequate housing or material goods
? erratic behaviour or continued problematic drug use
? polydrug use
? inability to provide adequate monitoring of 
infant wellbeing.
Most infants requiring treatment for NAS caused by 
opioid withdrawal will reach treatment threshold by 7 
days after birth (see Appendix 12: Duration of postnatal 
hospitalisation required to detect severe NAS). A few 
may have delayed withdrawal, requiring an extended 
stay in hospital. If mothers insist on going home against
medical advice, a community services (child protection)
notification should be considered. 
4.15.2 Safe discharge home of baby on 
pharmacological treatment
There are insufficient data to determine the safety of 
discharge of infants on morphine. Before an infant is
discharged home on morphine or phenobarbitone,
the treatment team must be satisfied of the safety of 
the home environment and of the parents’ parenting
abilities and ability to administer treatment. Careful and 
frequent supervision by the treatment team is required. 
Level of evidence: Consensus 
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This glossary is based on the National Drug Strategy 
‘Australia’s integrated framework 2004–2009’.
Aboriginal Health Worker: an Aboriginal and 
Torres Strait Islander person employed to provide
health services to Aboriginal and/or Torres Strait
Islander people.
abstinence: refraining from drug or alcohol use.
AIDS (acquired immune deficiency syndrome):
a syndrome defined by the development of serious
opportunistic infections, neoplasms or other life
threatening manifestations resulting from progressive
HIV-induced immunosuppression.
analgesia: pain relief.
benzodiazepines: a group of drugs used mainly as 
sedatives and muscle relaxants, and for the treatment of 
epilepsy (eg diazepam). Dependence on benzodiazepines
may develop quickly and be difficult to treat, 
consequently care must be used in prescribing.
Non-prescription use and over use is common. 
binge drinking: conventionally can refer to 
occasional bouts of heavy drinking by young and/or 
non-alcohol-dependent people, although not limited
to young people.
binge drug use: refers to occasional bouts of 
heavy use of any drug by young and/or non-drug-
dependent people.
blood-borne virus: a virus that can be transmitted
from an infected person to another person by blood-
to-blood contact, including through the sharing of 
injecting equipment.
BMT: buprenorphine maintenance treatment: a 
treatment for opioid dependence in which the 
dependent person is prescribed regular doses of 
buprenorphine, a long-acting partial agonist of opioid
receptors. The dose is in tablet form placed under the 
tongue. Like methadone maintenance, buprenorphine
maintenance reduces the subjective effect of and 
craving for short-acting opioids such as heroin and 
stabilises the dependent person in treatment. People 
in buprenorphine maintenance are less likely to inject
opioids, share injecting equipment, or engage in criminal
activity associated with illicit drug use.
buprenorphine: a long-acting partial agonist of 
opioid receptors. 
continuity of care: in these guidelines, refers to 
managing pregnant women so as to ensure that 
their health care is complete and continuous, with a 
minimum of changes in health care providers and with
a coordinated handover of health care responsibilities
when a change of health care providers is required.
dependence: see ‘drug dependence’.
dose titration: see ‘titration’.
drug: a substance that produces a psychoactive effect. 
Within the context of the National Drug Strategy 
‘drug’ is used generically to include tobacco, alcohol, 
pharmaceutical drugs and illicit drugs. The National
Drug Strategy also takes account of performance and 
image-enhancing drugs, and substances such 
as inhalants and kava.
drug dependence: drug dependence is characterised
by a strong desire to take a drug. Among the indicators
of dependence are impaired control over drug use, 
a higher priority given to drug use than to other 
activities and obligations, increased tolerance, physical
withdrawal symptoms, and repeated drug use to 
suppress withdrawal.
Glossary 
PAGE 52  National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn
drug-related harm: any adverse social, physical,
psychological, legal or other consequence of drug use 
that is experienced by a person using drugs or by people 
living with or otherwise affected by the actions of a 
person using drugs.
engagement: enrolling the woman in ongoing care; 
initiating the processes of care in such a way that the 
woman commits to continuing treatment. It is the 
quality of the therapeutic relationship that is important.
Entonox gas: a 50:50 mixture of oxygen and nitrous 
oxide gas, provided to women in labour as a form of 
pain relief.
evidence-informed practice: integration of the 
best available evidence with professional expertise to 
make decisions.
fetal alcohol syndrome (FAS): birth defects in an 
infant caused by the mother’s alcohol use during
pregnancy. Children with fetal alcohol syndrome have 
brain damage, facial deformities, and growth deficits.
Heart, liver, and kidney defects also are common, as 
well as vision and hearing problems. Affected individuals
have difficulties with learning, attention, memory, and 
problem solving. The syndrome is at the severe end of 
a spectrum of negative effects on the fetus caused 
by alcohol.
fetal alcohol spectrum disorder (FASD): a congenital
disorder caused by the mother’s alcohol use during
pregnancy. There is a wide range of these disorders, 
from minor defects in physical or mental development to 
the fetal alcohol syndrome.
gestation: pregnancy. The normal full-term gestation
is 40 weeks (280 days), measured from the first day 
of the mother’s last menstrual period to the birth. The 
gestational age is the estimated age of the fetus in the 
womb or of the neonate at birth.
harm-reduction strategies: strategies that are 
designed to reduce the impacts of drug-related harm 
on individuals and communities. Governments do not 
condone illegal risk behaviours such as injecting drug 
use: they acknowledge that these behaviours occur and 
that they have a responsibility to develop and implement
public health and law-enforcement measures designed
to reduce the harm that such behaviours can cause. 
harm minimisation: the primary principle underpinning
the National Drug Strategy. It refers to policies and 
programs aimed at reducing drug-related harm. It 
aims to improve health, social and economic outcomes 
for both the community and the individual, and 
encompasses a wide range of approaches, including
abstinence-oriented strategies. Australia’s harm-
minimisation strategy focuses on both licit and 
illicit drugs. Harm minimisation includes preventing
anticipated harm and reducing actual harm. 
harmful drug use: a pattern of drug use that has 
adverse social, physical, psychological, legal or other 
consequences for a person using drugs or people living
with or otherwise affected by the actions of a person 
using drugs. Hazardous drug use is any drug use that 
puts the person using drugs, or those living with or 
otherwise affected by the actions of a person using
drugs, at risk of these harmful consequences. Hazardous 
drug use includes any use of illicit drugs.
HCV: hepatitis C virus: a blood-borne virus that affects 
the liver. Transmission occurs when the blood of 
someone who is already infected with hepatitis C enters 
the bloodstream of another person, such as through 
sharing needles.
health care worker/practitioner: in these guidelines,
means any of the workers with professional training
(eg in medicine, nursing, psychology, social work, 
physiotherapy, drug and alcohol counselling or 
other therapies) who are involved in the care of 
pregnant women.
HIV: human immunodeficiency virus. A human retrovirus
that leads to acquired immune deficiency syndrome 
(AIDS). Transmission occurs through the exchange of 
bodily fluids, especially blood or semen.
illicit drug: a drug whose production, sale or possession
is prohibited. ‘Illegal drug’ is an alternative term.
infancy: from 28 days to the first year of life.
inhalants: substances inhaled for psychoactive effects—
for example, glues, aerosol sprays, paints, industrial
solvents, thinners, petrol and cleaning fluids.
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Intergovernmental Committee on Drugs (IGCD): one
of the advisory bodies supporting the Ministerial Council
on Drug Strategy, the Intergovernmental Committee on 
Drugs is a Commonwealth–State–Territory government 
forum which provides advice to Ministers on the full 
range of drug-related matters. It consists of senior
officers representing health and law-enforcement 
agencies in each Australian jurisdiction (appointed by 
their respective health and law-enforcement Ministers)
and other people with expertise in identified priority
areas (for example, representatives of the Australian
Customs Service, the Department of Education, Science
and Training and the Ministerial Advisory Committee on 
Aboriginal and Torres Strait Islander Affairs). The IGCD is
responsible for implementing the National Drug Strategic
Framework. For further information, refer to 
www.nationaldrugstrategy.gov.au/councils/igcd.htm
intervention: any action by a health care provider
intended to alter a health care outcome for a member 
of the population. Providing information, enrolling a 
patient in treatment, providing specific treatments or 
support services are all interventions.
kava: a drink or preparation obtained from the kava 
plant, Piper methysticum.
licit drug: a drug whose production, sale or possession
is not prohibited. ‘Legal drug’ is an alternative term.
methadone: a long-acting opioid drug taken orally. The 
liquid form is always used in the treatment of addictive
disorders, whereas the tablet formed is used in the 
treatment of cancer or other intractable pain.
MMT: methadone maintenance treatment: a treatment 
for opioid dependence in which the dependent person 
is prescribed regular doses of methadone, a long-acting
opioid drug. Methadone is given as a non-sweetened 
syrup taken orally. Methadone maintenance reduces the 
subjective effect of and craving for short-acting opioids
such as heroin, stabilises the dependent person in
treatment. People in methadone maintenance are 
less likely to inject opioids, share injecting equipment,
or engage in criminal activity associated with illicit
drug use.
Ministerial Council on Drug Strategy (MCDS): the 
peak policy- and decision-making body in relation to licit
and illicit drugs in Australia, the Ministerial Council on 
Drug Strategy brings together Commonwealth, State 
and Territory Ministers of Health and Law Enforcement, 
including the Minister responsible for Education. The 
role of the Council is to collectively determine national
policies and programs to reduce drug-related harm. 
The Ministerial Council ensures that the Australian
approach to harmful drug use is nationally coordinated
and integrated. Its collaborative approach is designed to 
achieve national consistency in policy principles, program 
development and The MCDS meets twice a year, usually 
in May and November and a Communique of the 
outcomes of the meeting is made publicly available.
For further information, refer to 
www.nationaldrugstrategy.gov.au/councils/mcds.htm.
miscarriage: spontaneous abortion; expulsion of the 
fetus from the womb before it is viable.
mortality: death. The mortality rate is the rate of death 
from a specified cause or in a specified population.
naloxone: a fast-acting opioid antagonist. Naloxone is
used to treat overdoses of opioid drugs. It competitively
displaces opioid agonists from opioid receptors, and can 
rapidly reverse symptoms and signs of opioid toxicity. 
naltrexone: a long acting, highly specific opioid
antagonist. Naltrexone blocks opioid receptors so that 
a person taking naltrexone will not experience the 
usual effects of taking opioids. Naltrexone competitively
displaces opioid agonists if they are present. Naltrexone 
maintenance treatment can help some people with a 
history of opioid-dependence remain abstinent.
narcotic drug: usually refers to opioids. It is also a 
preferred term in United Nations conventions, where it
may be used to refer more widely to other drugs.
National Drug Strategy: formerly the National
Campaign against Drug Abuse, was initiated in 1985, 
following a Special Premiers Conference. The National
Drug Strategy provides a comprehensive, integrated
approach to the harmful use of licit and illicit drugs 
and other substances. The aim is to achieve a balance 
between harm-reduction, demand-reduction and supply-
reduction measures to reduce the harmful effects of 
drugs in Australian society. The National Drug Strategy 
promotes partnerships between health, law enforcement 
and education agencies, drug users, people affected by 
drug-related harm, community-based organisations and 
industry, to reduce drug-related harm in Australia.
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National Drug Strategy Household Survey: the 
National Drug Strategy Household Survey series is one 
of the data-collections used to monitor trends and 
progress under the National Drug Strategy. The Surveys 
have been conducted nationally in 1985, 1988, 1991, 
1993, 1995, 1998, 2001 and 2004 and provide data on 
behaviour, knowledge and attitudes relating to drug use 
among people aged 14 years and over.
Needle and Syringe Programs: Authorised
programs for distributing, disposing of or selling
needles and syringes.
neonatal abstinence syndrome (NAS): a syndrome 
of drug withdrawal observed in infants of mothers 
physically dependent on drugs, manifested by non-
specific symptoms and signs in the infant. NAS is more 
common in infants born to opioid-dependent women 
than in infants born to women dependent on other 
drugs or alcohol. NAS in infants of opioid-dependent
mothers is manifested by neurological excitability, 
gastrointestinal dysfunction and autonomic signs.
There may be poor feeding, sleep-wake abnormalities,
vomiting, dehydration, poor weight gain and 
occasionally seizures.
neonatal period: first 28 days of life.
neonatal death: death of a live-born baby within the 
first 28 days from the time of birth.
nicotine: the principle drug in tobacco. It is a potent 
nerve poison and is included in many insecticides. In 
lower concentrations, the substance is a stimulant and 
is one of the main factors leading to the pleasure and 
habit-forming qualities of tobacco smoking.
nicotine replacement therapy (NRT): a treatment 
designed to help people stop smoking by providing
them with an alternative source of nicotine (such as 
nicotine chewing gum or skin patches). By removing the 
craving for nicotine, NRT reduces the desire to smoke.
opiate: see ‘opioid’.
opioid: the generic term applied to alkaloids and their
derivatives obtained from the opium poppy (Papaver 
somniferum), including methadone, morphine, heroin
and codeine.
opioid treatment program: a program to provide
pharmacotherapies for opioid dependent people, 
such as methadone maintenance or buprenorphine
maintenance.
optimum therapeutic dose: the dose of a drug that 
achieves the best possible treatment of the patient.
Determining the optimum therapeutic dose involves
balancing the beneficial effects and side effects of 
the drug. 
overdose: the use of a drug in an amount that causes 
acute adverse physical or mental effects. Overdose may 
produce transient or lasting effects and can sometimes
be fatal.
partnership approach: in the context of the National
Drug Strategy, a partnership approach is defined as a 
close working relationship between the Commonwealth 
government, State and Territory governments, local 
governments, affected communities (including drug 
users and those affected by drug-related harm), 
business and industry, community-based organisations,
professional workers and research institutions.
PCR: polymerase chain reaction. This reaction can be 
used to amplify specific fragments of DNA or RNA in a 
sample (such as a blood sample). PCR tests are used for 
the diagnosis of viral infections such as HIV. 
perinatal period: from 20 completed weeks gestation
up to 7 days post delivery.
perinatal death; perinatal mortality: stillbirths plus 
any deaths up to 7 days from the time of birth.
pharmacotherapy: treatment using drugs. 
Pharmacotherapies for drug dependence include
methadone maintenance or buprenorphine maintenance
as a treatment for heroin dependence and nicotine
replacement therapy as a treatment for tobacco 
dependence.
polydrug use: the use of more than one drug, 
simultaneously or at different times. The term ‘polydrug 
user’ is often used to distinguish a person with a varied
pattern of drug use from someone who uses one kind
of drug exclusively.
population group: can refer to an entire population
group, as defined by geographical location, or to sub-
groups defined by geographical location, age, risk factor, 
or possession of a common condition or disease.
preterm labour and birth (delivery): birth after 
20 weeks and before 37 weeks gestation
prevention: within the context of the National Drug 
Strategy, prevention refers to measures that prevent or 
delay the onset of drug use as well as measures that 
protect against risk and prevent and reduce the harms 
associated with drug supply and use.
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psychoactive effects: effects that alter mental 
processes—mood, cognition, thinking or behaviour.
psychostimulant: a drug that activates, enhances 
or increases neural activity. Caffeine, nicotine,
amphetamines, cocaine and MDMA (ecstasy) are the 
psychostimulants most commonly used in Australia.
relapse: the recurrence of a disease after a seeming
recovery; in relation to drug dependence, this means 
a return to using the drug of dependence after a period
of abstinence.
sudden infant death syndrome (SIDS): the sudden 
death of an infant which remains unexplained after 
a full paediatric autopsy including toxicology, review
of medical and social history, and assessment of the 
circumstances of the death.
smoking status: a description of an individual’s current 
smoking habits, such as ‘Never smoked’, ‘Quit smoking
[how long ago]’, ‘Trying to quit’, ‘Cutting down [from 
what to what]’, ‘Current smoker [number of cigarettes 
per day]’. 
stillbirth: an in utero death delivering after 20th week 
of pregnancy 
sudden unexpected deaths in infancy (SUDI): death 
of an infant less than 12 months of age, where the 
death was sudden, and was unexpected at the time.
The term ‘unexpected’ indicates that the cause of death 
was not recognised before the event, although it may 
be diagnosed at autopsy . SUDI usually includes death 
due to SIDS and to other ill-defined causes (such as 
sleeping accidents).
teratogen: an agent that can cause malformations of 
an embryo or fetus
titration: the process of finding the optimum
therapeutic dose of a drug for an individual by observing
the effect of each dose on the individual and adjusting
subsequent doses up or down accordingly. Dose titration
can be guided by observations of signs and symptoms 
in the individual and/or by biochemical tests (such as 
blood tests).
user groups: community-based organisations
representing the interests of drug users.
vertical transmission: transmission of an infection from 
mother to fetus or infant.
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National Quitline number 13 7848 (cost of local call)
Australian Capital Territory
Alcohol and Drug Service (ADIS) 02 6207 9977
New South Wales
NSW Drug and Alcohol Specialist Advisory Service (DASAS) 02 9361 8006
(24-hour health professionals telephone service) 1800 023 687 (outside Sydney)
Northern Territory
Drug and Alcohol Clinical Advisory Service (DACAS-NT) 1800 111 092
Queensland
Queensland Drug Information Centre 07 3636 7098
Therapeutic Advice and Information Service 1300 138 677
Alcohol and Drug Information Service (ADIS) 07 3236 2414
(24-hour counselling, information and referral) 1800 177 833 (outside Brisbane)
South Australia
Alcohol and Drug Information Service (ADIS) in SA 1300 13 13 40
Tasmania
Drug and Alcohol Clinical Advisory Service (DACAS) 1800 630 093
Victoria
The Women’s Alcohol & Drug Service (pregnancy care and professional support) 03 9344 3631
DirectLine (24 hour counselling and referral) 1800 888 236
Quit Victoria 03 9663 7777
Western Australia
Antenatal Chemical Dependency Clinic (ACDC) 
Women’s and Children’s Health Service 08 93401379
Appendix 1: Advice for health care 
workers on drugs and alcohol 
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National Quitline number 13 7848 (cost of local call)
Australian Capital Territory
Alcohol and Drug Service (ADIS) 02 6207 9977
(24-hour counselling, information and referral)
New South Wales
MotherSafe: the Statewide Medications in Pregnancy and Lactation Advisory Service 02 9382 6539
The Royal Hospital for Women, Barker Street, Randwick 2031 Freecall 1800 647 848
Alcohol and Drug Information Service (ADIS) 02 9361 8000
(24-hour counselling, information and referral) 1800 422 599 (outside Sydney)
Poisons’ Information Centre 13 11 26
Northern Territory
ADIS NT (24-hour counselling, information and referral) 1800 131 350
Drug and Poisons Information Centre 
Royal Darwin Hospital Specialty Tropical Medicine 08 8922 8424
Pregnancy Drug Information Centre, Royal Darwin Hospital 08 8922 8424
Queensland
National Prescribing Service Limited (NPS) Medicines Line
Monday to Friday, 9am to 6pm EST 1300 888 763
Alcohol and Drug Information Service (ADIS) 07 3236 2414
(24-hour counselling, information and referral) 1800 177 833 (outside Brisbane)
South Australia
Alcohol and Drug information Service (ADIS)
(24-hour counselling, information and referral) 1300 131 340
Drugs in Pregnancy Service
Women’s and Children’s Hospital, 9am – 5pm Monday to Friday 08 8161 7222
Tasmania
Alcohol and Drug Information Service (ADIS)
(24-hour counselling, information and referral) 1800 811 994
Victoria
Drug information Centre
The Royal Women’s Hospital, Melbourne, 9am – 5pm Monday to Friday 03 9344 2277
Western Australia
Antenatal Chemical Dependency Clinic (ACDC)
Women’s and Children’s Health Service 08 93401379
Appendix 2: Advice for consumers 
on drugs, alcohol and medications 
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Appendix 3: Examples of drug 
use assessment tools
WHO - ASSIST V3.0
CLINICIAN ID CLINIC
PATIENT ID DATE
INTRODUCTION  (Please read to patient.  Can be adapted for local circumstances )
(Many drugs & medications can affect your health.  It is important for your health care provider to have 
accurate information about your use of various substances, in order to provide the best possible care.) 
The following questions ask about your experience of using alcohol, tobacco produces and other drugs 
across your lifetime and in the past three months.  These substances can be smoked, swallowed, snorted, 
inhaled, injected or taken in the form of pills (show drug card). 
Some of the substances listed may be prescribed by a doctor (like amphetamines, sedatives, pain 
medications).  For this interview, we will not record medications that are used as prescribed by your doctor.  
However, if you have taken such medications for reasons other than prescription, or taken them more 
frequently or at higher doses than prescribed, please let me know.  While we are also interested in knowing 
about your use of various illicit drugs, please be assured that information on such use will be treated as 
strictly confidential. 
NOTE: BEFORE ASKING QUESTIONS, GIVE ASSIST RESPONSE CARD TO PATIENT
Question 1
In your life, which of the following substances have you 
ever used? (NON-MEDICAL USE ONLY)
No Yes
a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 3
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 3
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 3
d.  Cocaine (coke, crack, etc.) 0 3
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 3
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 3
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 3
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 3
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 3
j.  Other - specify: 0 3
Probe if all answers are negative: 
“Not even when you were in school?” 
If "No" to all items, stop interview. 
If "Yes" to any of these items, ask 
Question 2 for each substance ever used.
Example 1: The Alcohol, Smoking and Substance 
Involvement Screening Test (ASSIST)
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Question 2 
In the past three months, how often have you used 
the substances you mentioned (FIRST DRUG, 
SECOND DRUG, ETC)? N
e
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a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 2 3 4 6
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 2 3 4 6
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 2 3 4 6
d.  Cocaine (coke, crack, etc.) 0 2 3 4 6
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 2 3 4 6
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 2 3 4 6
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 2 3 4 6
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 2 3 4 6
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 2 3 4 6
j.  Other - specify: 0 2 3 4 6
If "Never" to all items in Question 2, skip to Question 6. 
If any substances in Question 2 were used in the previous three months, continue with 
Questions 3, 4 & 5 for each substance used. 
Question 3 
During the past three months, how often have you 
had a strong desire or urge to use (FIRST DRUG, 
SECOND DRUG, ETC)? N
e
v
e
r 
O
n
c
e
 o
r 
T
w
ic
e
M
o
n
th
ly
W
e
e
k
ly
 
D
a
il
y
 o
r 
A
lm
o
s
t 
D
a
il
y
a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 3 4 5 6
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 3 4 5 6
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 3 4 5 6
d.  Cocaine (coke, crack, etc.) 0 3 4 5 6
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 3 4 5 6
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 3 4 5 6
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 3 4 5 6
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 3 4 5 6
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 3 4 5 6
j.  Other - specify: 0 3 4 5 6
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Ask Questions 6 & 7 for all substances ever used  (i.e. those endorsed in Question 1) 
Question 6 
Has a friend or relative or anyone else ever
expressed concern about your use of 
(FIRST DRUG, SECOND DRUG, ETC.)?
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a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 6 3
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 6 3
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 6 3
d.  Cocaine (coke, crack, etc.) 0 6 3
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 6 3
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 6 3
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 6 3
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 6 3
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 6 3
j.  Other – specify: 0 6 3
Question 7 
Have you ever tried and failed to control, cut down or stop 
using (FIRST DRUG, SECOND DRUG, ETC.)? N
o
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a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 6 3
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 6 3
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 6 3
d.  Cocaine (coke, crack, etc.) 0 6 3
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 6 3
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 6 3
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 6 3
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 6 3
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 6 3
j.  Other – specify: 0 6 3
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Question 8 
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Have you ever used any drug by injection?
(NON-MEDICAL USE ONLY)
0 2 1
IMPORTANT NOTE: 
Patients who have injected drugs in the last 3 months should be asked about their pattern of 
injecting during this period, to determine their risk levels and the best course of intervention.
PATTERN OF INJECTING INTERVENTION GUIDELINES
Once weekly or less  or
Fewer than 3 days in a row
Brief Intervention including “risks
associated with injecting” card
More than once per week or
3 or more days in a row
Further assessment and more
intensive treatment*
HOW TO CALCULATE A SPECIFIC SUBSTANCE INVOLVEMENT SCORE.
For each substance (labelled a. to j.) add up the scores received for questions 2 through 7 inclusive.  Do not
include the results from either Q1 or Q8 in this score.  For example, a score for cannabis would be calculated
as: Q2c + Q3c + Q4c + Q5c + Q6c + Q7c
Note that Q5 for tobacco is not coded, and is calculated as: Q2a + Q3a + Q4a + Q6a + Q7a
THE TYPE OF INTERVENTION IS DETERMINED BY THE PATIENT’S SPECIFIC SUBSTANCE INVOLVEMENT SCORE
Record specific
substance score
no
intervention
receive brief 
intervention
more intensive
treatment * 
a. tobacco 0 - 3 4 - 26 27+
b. alcohol 0 - 10 11 - 26 27+
c. cannabis 0 - 3 4 - 26 27+
d. cocaine 0 - 3 4 - 26 27+
e. amphetamine 0 - 3 4 - 26 27+
f. inhalants 0 - 3 4 - 26 27+
g. sedatives 0 - 3 4 - 26 27+
h. hallucinogens 0 - 3 4 - 26 27+
i. opioids 0 - 3 4 - 26 27+
j. other drugs 0 - 3 4 - 26 27+
NOTE: *FURTHER ASSESSMENT AND MORE INTENSIVE TREATMENT may be provided by the health professional(s)
within your primary care setting, or, by a specialist drug and alcohol treatment service when available.
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WHO ASSIST V3.0   RESPONSE CARD FOR PATIENTS
Response Card - substances 
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 
b. Alcoholic beverages (beer, wine, spirits, etc.) 
c. Cannabis (marijuana, pot, grass, hash, etc.) 
d. Cocaine (coke, crack, etc.) 
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 
f. Inhalants (nitrous, glue, petrol, paint thinner, etc.) 
g. Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 
h. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 
i. Opioids (heroin, morphine, methadone, codeine, etc.) 
j. Other - specify: 
Response Card (ASSIST Questions 2 – 5) 
Never: not used in the last 3 months 
Once or twice: 1 to 2 times in the last 3 months. 
Monthly: 1 to 3 times in one month. 
Weekly: 1 to 4 times per week. 
Daily or almost daily: 5 to 7 days per week. 
Response Card (ASSIST Questions 6 to 8) 
No, Never 
Yes, but not in the past 3 months 
Yes, in the past 3 months 
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Alcohol, Smoking and Substance Involvement Screening Test
(WHO ASSIST V3.0) Feedback REPORT CARD for Patients
Name________________________________ Test Date _____________________ 
Specific Substance Involvement Scores 
Substance Score Risk Level
a. Tobacco products
0-3 Low  
4-26 Moderate 
27+ High 
b. Alcoholic Beverages
0-10 Low 
11-26 Moderate 
27+ High 
c. Cannabis
0-3 Low  
4-26    Moderate 
27+ High 
d. Cocaine
0-3 Low  
4-26    Moderate 
27+ High 
e. Amphetamine type stimulants  
0-3 Low  
4-26    Moderate 
27+ High 
f. Inhalants
0-3 Low  
4-26    Moderate 
27+ High 
g. Sedatives or Sleeping Pills
0-3 Low  
4-26    Moderate 
27+ High 
h. Hallucinogens  
0-3 Low  
4-26    Moderate 
27+ High 
i. Opioids
0-3 Low  
4-26    Moderate 
27+ High 
j. Other - specify 
0-3 Low  
4-26    Moderate 
27+ High 
What do your scores mean? 
Low: You are at low risk of health and other problems from your current pattern of use.
Moderate: You are at risk of health and other problems from your current pattern of substance 
use.
High: You are at high risk of experiencing severe problems (health, social, financial, legal, 
relationship) as a result of your current pattern of use and are likely to be dependent
Are you concerned about your substance use? 
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a.
tobacco 
Your risk of experiencing these harms is:……… 
Regular tobacco smoking is associated with: 
Low ? Moderate ? High ?
 (tick one) 
Premature aging, wrinkling of the skin 
Respiratory infections and asthma 
High blood pressure, diabetes 
Respiratory infections, allergies and asthma in children of smokers 
Miscarriage, premature labour and low birth weight babies for pregnant women 
Kidney disease 
Chronic obstructive airways disease 
Heart disease, stroke, vascular disease 
Cancers  
b.
alcohol
Your risk of experiencing these harms is:……… 
Regular excessive alcohol use is associated with:
Low ? Moderate ? High ?
 (tick one) 
Hangovers,  aggressive and violent behaviour,  accidents and injury 
Reduced sexual performance,  premature ageing 
Digestive problems,  ulcers,  inflammation of the pancreas,  high blood pressure 
Anxiety and depression,  relationship difficulties,  financial and work problems 
Difficulty remembering things and solving problems 
Deformities and brain damage in babies of pregnant women 
Stroke,  permanent brain injury,  muscle and nerve damage 
Liver disease,  pancreas disease 
Cancers,  suicide 
c.
cannabis 
Your risk of experiencing these harms is:…… 
Regular use of cannabis is associated with:
Low ? Moderate ? High ?
 (tick one) 
Problems with attention and motivation  
Anxiety, paranoia, panic, depression 
Decreased memory and problem solving ability 
High blood pressure 
Asthma, bronchitis 
Psychosis in those with a personal or family history of schizophrenia 
Heart disease and chronic obstructive airways disease 
Cancers 
National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn  PAGE 67
d.
cocaine
Your risk of experiencing these harms is:…. 
Regular use of cocaine is associated with: 
Low ? Moderate ? High ?
 (tick one) 
Difficulty sleeping,  heart racing,  headaches,  weight loss 
Numbness,  tingling,  clammy skin, skin scratching or picking 
Accidents and injury,  financial problems 
Irrational thoughts 
Mood swings - anxiety, depression, mania 
Aggression and paranoia 
Intense craving, stress from the lifestyle 
Psychosis after repeated use of high doses 
Sudden death from heart problems 
e.
amphetamine
type stimulants 
Your risk of experiencing these harms is:……. 
Regular use of amphetamine type stimulants is 
associated with: 
Low ? Moderate ? High ?
 (tick one) 
Difficulty sleeping,  loss of appetite and weight loss,  dehydration 
jaw clenching,  headaches,  muscle pain 
Mood swings –anxiety,  depression,  agitation,  mania,  panic,  paranoia 
Tremors,  irregular heartbeat,  shortness of breath 
Aggressive and violent behaviour 
Psychosis after repeated use of high doses 
Permanent damage to brain cells 
Liver damage,  brain haemorrhage,  sudden death (from ecstasy) in rare situations 
f.
inhalants
Your risk of experiencing these harms is:….……. 
Regular use of inhalants is associated with: 
Low ? Moderate ? High ?
 (tick one) 
Dizziness and hallucinations,  drowsiness,  disorientation,  blurred vision 
Flu like symptoms,  sinusitis,  nosebleeds 
Indigestion,  stomach ulcers 
Accidents and injury 
Memory loss,  confusion,  depression,  aggression 
Coordination difficulties,  slowed reactions,  hypoxia 
Delirium,  seizures,  coma,  organ damage (heart,  lungs,  liver,  kidneys) 
Death from heart failure 
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g.
sedatives 
Your risk of experiencing these harms is: 
Regular use of sedatives is associated with: 
Low ?    Moderate ?    High ?
(tick one)
Drowsiness, dizziness and confusion 
Difficulty concentrating and remembering things 
Nausea,  headaches,  unsteady gait 
Sleeping problems 
Anxiety and depression 
Tolerance and dependence after a short period of use. 
Severe withdrawal symptoms 
Overdose and death if used with alcohol, opioids or other depressant drugs. 
h.
hallucinogens 
Your risk of experiencing these harms is:……….. 
Regular use of hallucinogens is associated with:
Low ?    Moderate ?    High ?
 (tick one) 
Hallucinations (pleasant or unpleasant) – visual, auditory, tactile, olfactory 
Difficulty sleeping 
Nausea and vomiting 
Increased heart rate and blood pressure 
Mood swings 
Anxiety,  panic,  paranoia 
Flash-backs 
Increase the effects of mental illnesses such as schizophrenia 
i.
opioids
Your risk of experiencing these harms is: 
Regular use of opioids is associated with: 
Low ?    Moderate ?    High ?
 (tick one) 
Itching,  nausea and vomiting 
Drowsiness 
Constipation,  tooth decay 
Difficulty concentrating and remembering things 
Reduced sexual desire and sexual performance 
Relationship difficulties 
Financial and work problems, violations of law 
Tolerance and dependence,  withdrawal symptoms 
Overdose and death from respiratory failure 
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WHO-ASSIST Risks of Injecting Card – Information for Patients 
Using substances by injection increases the risk of harm from substance use.
This harm can come from: 
?? The substance 
??If you inject any drug you are more likely to become dependent. 
??If you inject amphetamines or cocaine you are more likely to experience psychosis. 
??If you inject heroin or other sedatives you are more likely to overdose.
?? The injecting behaviour 
??If you inject you may damage your skin and veins and get infections.
??You may cause scars, bruises, swelling, abscesses and ulcers.
??Your veins might collapse.
??If you inject into the neck you can cause a stroke.
?? Sharing of injecting equipment 
??If you share injecting equipment (needles & syringes, spoons, filters, etc.) you are 
more likely to spread blood borne virus infections like Hepatitis B, Hepatitis C and 
HIV.
??It is safer not to inject 
??If you do inject:
??always use clean equipment (e.g., needles & syringes, spoons, filters, etc.)
??always use a new needle and syringe 
??don’t share equipment with other people 
??clean the preparation area
??clean your hands 
??clean the injecting site 
??use a different injecting site each time
??inject slowly 
??put your used needle and syringe in a hard container and dispose of it safely
??If you use stimulant drugs like amphetamines or cocaine the following tips will
help you reduce your risk of psychosis.
??avoid injecting and smoking 
??avoid using on a daily basis 
??If you use depressant drugs like heroin the following tips will help you reduce
your risk of overdose. 
??avoid using other drugs, especially sedatives or alcohol, on the same day 
??use a small amount and always have a trial “taste” of a new batch 
??have someone with you when you are using
??avoid injecting in places where no-one can get to you if you do overdose 
??know the telephone numbers of the ambulance service
Source: World Health Organisation ASSIST tool
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Women’s alcohol and drug service worker:
Date of screening:
Client:      Past     New
Client details
Name:
Address:
Telephone:
Mobile:
UR:  
DOB:  Age:  
Country of birth:  
Cultural background:  
Occupation:  
Language used at home:  
Interpreter needed:      YES      NO
Level of education:
Aboriginal or Torres Strait Islander:      YES      NO
Literacy difficulties:      YES      NO
Date of referral:  
Referee:  
Address:
Telephone:
General practitioner details
Name:
Address:
Telephone:
Fax:
Example 2: Women’s Alcohol and Drug Client 
Assessment Tool
The Royal Womens Hospital
Women’s Alcohol And Drug Service (WADS)
132 Grattan Street, Carlton 3053, Australia,
Telephone (03) 9344 3631 www.rwh.org.au/wads
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Pharmacotherapy prescriber
Name:
Address:
Telephone:
Fax:
Current pharmacy details
Name:
Address:
Telephone:
Fax:
Support service details
Contact person:
Agency:
Address:
Telephone:
Fax:
Previous Pregnancies
1. Year Outcome  
Gestation  F/M
Delivery mode 
2. Year Outcome  
Gestation  F/M
Delivery mode 
3. Year Outcome  
Gestation  F/M
Delivery mode 
Current Pregnancy
Have you had a positive pregnancy test:  YES   NO
Expected date of delivery:  
Gestation (in weeks):  
Was this pregnancy planned:      YES      NO
Have you had antenatal care:      YES      NO
If yes with whom:  
Commencement date: 
Medical/psychiatric history
Past medical/psychiatric history:
Current medical/psychiatric history:
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Drug use history
Heroin
Age at first use: 
Method of use:   
Age at heaviest use:  
Amount used at this time:
How many times a day did you use:  
Were there any precipitating factors:    YES    NO
peer pressure
relationship/family breakdown
financial hardship
abuse/domestic violence
Other:
Age when you first sought to reduce/address 
your drug use: 
self detox
home detox/supervised help
pharmacotherapy
specialist AOD counselling service
self-help support group
general practitioner
AOD treatment residential
general counselling
Other:
Current heroin use
Amount used: How many times a day: 
Method of use: 
Has your use changed recently?    YES    NO
Reason for change:                                      
pregnancy 
relationship
financial hardship
legal issues
desire to change
Other:
Date and time last used: 
Injecting drug use history
Do you share injecting equipment?
Present:     YES    NO
Past:     YES    NO
Have you shared injecting
equipment with a partner:   YES    NO
Have you shared injecting equipment
with people other than your partner:    YES    NO 
Alcohol use history
Age at first use: 
Age at heaviest use:  
Amount used at this time:
Were there any precipitating factors:    YES    NO
peer pressure
relationship/family breakdown
financial hardship
abuse/domestic violence
Other:
Alcohol current use
Amount used: 
Has your use changed recently:    YES    NO
Reason for change:
pregnancy                                                                                    
relationship
financial hardship
legal issues
desire to change
Other:
Date and time last used alcohol:  
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Amphetamines use history
Age at first use: 
Method of use:   
Age at heaviest use:  
Amount used at this time:
How many times a day did you use:  
Were there any precipitating factors:   YES   NO
peer pressure
relationship/family breakdown
financial hardship
abuse/domestic violence
Other:
Amphetamine current use
Method of use:   
How many times a day: 
Has your use changed recently:    YES    NO
Reason for change:
pregnancy
relationship
financial hardship
legal issues
desire to change
Other:
Date and time of last use: 
Cannabis use history
Age at first use: 
Method of use:   
Age at heaviest use:  
Amount used at this time:
How many times a day did you use:  
Were there any precipitating factors:   YES   NO
peer pressure
relationship/family breakdown
financial hardship
abuse/domestic violence
Other:
Cannabis current use
Amount used: 
Method of use:   
How many times a day: 
Has your use changed recently:    YES    NO
Reason for change:
pregnancy
relationship
financial hardship
legal issues
desire to change
Other:
Date and time of last use: 
Benzodiapines use history
Age at first use: 
Method of use:   
Age at heaviest use:  
Amount used at this time:
How many times a day did you use: 
Were there any precipitating factors:    YES    NO
peer pressure
relationship/family breakdown
financial hardship
abuse/domestic violence
Other:
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Benzodiapines current use
Benzo names: 
Amount used: 
Method of use:   
How many times a day: 
Has your use changed recently:    YES    NO
Reason for change:
pregnancy
relationship
financial hardship
legal issues
desire to change
Other:
Date and time of last use: 
Ecstacy use history
Age at first use:  
Age at heaviest use:  
Amount used at this time:
How many times a day did you use: 
Were there any precipitating factors:    YES    NO
peer pressure
relationship/family breakdown
financial hardship
abuse/domestic violence
Other:
Ecstacy current use
Amount used: 
Method of use:  
How many times a day: 
Has your use changed recently:    YES    NO
Reason for change:
Pregnancy 
Relationship                                                                                      
Financial hardship
Legal issues
Desire to change
Other:
Date and time of last use: 
LSD use history
Age at first use: 
Age at heaviest use: 
Method of use:   
Amount used at this time:
How many times a day did you use: 
Were there any precipitating factors:    YES    NO
peer pressure
relationship/family breakdown
financial hardship
abuse/domestic violence
Other:
LSD current use
Amount used: 
Method of use:   
How many times a day: 
Has your use changed recently:    YES    NO
Reason for change:
pregnancy
relationship
financial hardship
legal issues
desire to change
Other:
Date and time of last use: 
Inhalants use history
Age at first use: 
Method of use:   
Age at heaviest use:  
Amount used at this time:
How many times a day did you use:  
Were there any precipitating factors:   YES   NO
peer pressure
relationship/family breakdown
financial hardship
abuse/domestic violence
Other:
National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn  PAGE 75
Inhalants current use
Names:
Amount used: 
Method of use:   
How many times a day: 
Has your use changed recently:    YES    NO
Reason for change:
pregnancy
relationship
financial hardship
legal issues
desire to change
Other:
Date and time of last use: 
Tobacco use history
Age at first use: 
Age at heaviest use:  
How many times a day did you use:  
Were there any precipitating factors:    YES    NO
peer pressure
relationship/family breakdown
financial hardship
abuse/domestic violence
Other:
Tobacco current use
How many times a day: 
Has your use changed recently:    YES    NO
Reason for change:
pregnancy
relationship
financial hardship
legal issues
desire to change
Other:
Cocaine use history
Age at first use:  
Age at heaviest use:  
Amount used at this time:
How many times a day did you use: 
Were there any precipitating factors:    YES    NO
peer pressure
relationship/family breakdown
financial hardship
abuse/domestic violence
Other:
Current cocaine use
Amount used: 
Method of use:  
How many times a day: 
Has your use changed recently:    YES    NO
Reason for change:
Pregnancy 
Relationship                                                                                      
Financial hardship
Legal issues
Desire to change
Other:
Date and time of last use: 
Other substance use
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Pharmacotherapy
(methadone, buprenorphine, naltrexone)
Age at first use: 
How many times daily:
Method of use:   
Amount used at this time:
Were there any precipitating factors:    YES    NO
peer pressure
relationship/family breakdown
financial hardship
abuse/domestic violence
Other:
Current pharmacotherapy
Amount used: 
Method of use:   
Has your use changed recently:    YES    NO
Reason for change:
Pregnancy
Relationship
Financial hardship
Legal issues
Desire to change
Other:
Date and time of last use: 
Prescription medication 
History
Current medication
Partner details
Name:
Address: 
Age: DOB:  
Is your partner the father of the baby:   YES   NO
Is the baby’s father aware of the pregnancy:
 YES    NO
How long have you and your partner been together:
Does your partner use drugs:    YES    NO
Partner’s current drug use: 
Method:
Amount:  
How many times a day: 
Is your partner’s drug use a problem for you:
 YES    NO
Has your partner’s use changed recently 
and reasons for change: 
Is he/she in treatment: 
Partner’s legal issues 
none bond  
cbo parole   
 ico remand   
drug treatment order prison
bail/charged court order
combined custody and community treatment
Other:
Partners previous children
Does your partner have any other children:
 YES    NO
Children details
Name:
DOB:
Name:
DOB:
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Have DHS/child protection been involved:
 YES    NO
Details (order): 
Partner’s history with DHS/child protection
Details:
Clients history with DHS/child protection
Have you been a client of child protection as a child:
 YES    NO
Details:
Current involvement
permanent care order
guardianship order
custody to the secretary order
 interium protection order
supervision order
unknown
Further details:
Client’s children
Children details
Name:
DOB:
Name:
DOB:
Name:
DOB:
Have DHS/CP been involved:    YES    NO
permanent care order
guardianship order
custody to the secretary order
 interium protection order
supervision order
unknown
Further information:
Clients legal situation
none bond  
cbo parole   
 ico remand   
drug treatment order prison
bail/charged court order
combined custody and community treatment
Other:
Further information:
Previous incarceration   
Details:
Financial
Income:
employed full-time pensioner   
self employed student
employed part-time home duties   
sickness benefits unemployment
Other:
Referral to: 
Housing
What type of housing are you currently in:
Living arrangement:
alone spouse/partner   
alone with spouse/partner
child(ren)   and child(ren)
friend(s) parent(s)   
relatives   group household   
Other:
PAGE 78  National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn
Accommodation
house/flat – owned house/flat – rented
rooming/boarding hostel (supported)
psychiatric home/hostel shelter/refuge
AOD treatment service no fixed abode
caravan park    
Other:
How long have you been there: 
Have you been homeless in the past 12 months:   
 YES    NO
Do you plan to move to more suitable housing:   
 YES    NO
Do you need housing assistance:    YES    NO
Details:
Do you have a housing worker:    YES    NO
Name:
Address: 
Phone:
Referral made to housing worker:    YES    NO
Details:
Genogram
Significant relationship:
Abuse and domestic violence issues
In the past have you been exposed to:
Verbal abuse, physical trauma, 
sexual assault and/or emotional trauma:
What age were you at the time:
Further information:
Worker access issues for home visits
Type of housing:    
 house    flat    apartment 
Access issues (stairs, parking):
Details:
Pets at the home:  
 unknown    no    yes    type:
Are pets restrained:    no    yes
Weapons in the home:    
 unknown    no    yes    type:
Past/current violence towards workers:   
 no    yes   
Details:
Past/current violence in the home:   
 unknown    no    yes 
Details:
Suicide risk history
Past
Attempt:
Self harm: 
Ideation:
Treatment: 
Current
Attempt:
Self harm: 
Ideation:
Treatment: 
Individual treatment plan
Short term goals: 
Medium term goals: 
Long term goals: 
Source: Women’s Alcohol and Drug Service (WADS), 
The Royal Women’s Hospital, Melbourne, Victoria.
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Example 1: The short opiate withdrawal scale
Please put a check mark in the appropriate box if you have suffered from any of the following conditions
in the last 24 hours:
None Mild Moderate Severe
Feeling Sick
Stomach Cramps
Muscle Spasms/Twitching
Feelings of Coldness
Heart Pounding
Muscular Tension
Aches and Pains
Yawning
Runny Eyes
Insomnia/Problems Sleeping
Scoring: None = 0   Mild = 1   Moderate = 2   Severe = 3
Gossop M. ‘The development of a Short Opiate Withdrawal Scale (SOWS)’. Addictive Behaviors. 15(5), pp.487-90, 1990.
Appendix 4: Examples of assessment 
scales for opioid withdrawal in adults
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Example 2: a. The subjective opiate withdrawal scale (SOWS)
Date: Time:
Please score each of the 16 items below according 
to how you feel now (circle one number)
Symptom not at all a little moderately quite a bit extremely
1 I feel anxious 0 1 2 3 4
2 I feel like yawning 0 1 2 3 4
3 I am perspiring 0 1 2 3 4
4 My eyes are tearing 0 1 2 3 4
5 My nose is running 0 1 2 3 4
6 I have goosebumps 0 1 2 3 4
7 I am shaking 0 1 2 3 4
8 I have hot flushes 0 1 2 3 4
9 I have cold flushes 0 1 2 3 4
10 My bones and muscles ache 0 1 2 3 4
11 I feel restless 0 1 2 3 4
12 I feel nauseous 0 1 2 3 4
13 I feel like vomiting 0 1 2 3 4
14 My muscles twitch 0 1 2 3 4
15 I have stomach cramps 0 1 2 3 4
16 I feel like using now 0 1 2 3 4
Total score range 0-64.
Example 2: b. Objective opioid withdrawal scale (OOWS)
Date: Time:
Observe the patient during a 5 minute observation period then indicate a score for each of the opioid withdrawal
signs listed below (items 1-13). Add the scores for each item to obtain the total score
Sign Measures Score
1 Yawning 0 = no yawns 1 = ? 1 yawn
2 Rhinorrhoea 0 = < 3 sniffs 1 = ? 3 sniffs
3 Piloerection (observe client’s arm) 0 = absent 1 = present
4 Perspiration 0 = absent 1 = present
5 Lacrimation 0 = absent 1 = present
6 Tremor (hands) 0 = absent 1 = present
7 Mydriasis (pupil dilation) 0 = absent 1 = ? 3 mm
8 Hot and Cold flushes 0 = absent 1 = shivering / huddling for warmth
9 Restlessness 0 = absent 1 = frequent shifts of position
10 Vomiting 0 = absent 1 = present
11 Muscle twitches 0 = absent 1 = present
12 Abdominal cramps (Holding stomach) 0 = absent 1 = Holding stomach
13 Anxiety 0 = absent 1 = mild - severe
TOTAL SCORE
Total score range 0-13 
Handelsman L, Cochrane K, Aronseon M, Ness R, Rubinstein K, Kanof P 1987 ‘Two new rating scales for opiate
withdrawal’ American Journal of Drug and Alcohol Abuse 13 (3), p. 293-308.
Source: Women’s Alcohol and Drug Service (WADS), Royal Women’s Hospital, Melbourne Victoria.
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Appendix 5: Examples of safe sleeping 
practices information
Example 1: Women’s Alcohol and Drug Service Safe 
Sleeping brochure
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Source: SIDS and Kids: Safe sleeping www.sidsandkids.org/safe_sleeping.html.
For more information, see SIDS and Kids www.sidsandkids.org/home.html
Or you can contact National Health Promotion Manager Tel. 02 6287 4255
sids&kids
safe sleeping
Lullabies aren’t the only things
you’ll need to know to put
your baby to sleep
Example 2: Sids and Kids Safe Sleeping brochure
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Appendix 6: Examples of discharge 
assessment checklists
Example 1: The Royal Women’s Hospital Assessment 
for Infant Home Based Withdrawal
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Source: Women’s Alcohol and Drug Service (WADS), Royal Women’s Hospital, Melbourne Victoria.
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Example 2: Chemical Use in Pregnancy Discharge Checklist
Chemical Use in Pregnancy (CUPS) Discharge Checklist
(tick appropriate boxes)
 Administration of medication
 Signs and symptoms of NAS
 Completed Medicare form
 Emergency contact numbers
 SIDS information and safe sleeping for under 2s
 Parentcraft Skills
  Sleep and settling  
  Independent / Supervised / Assisted
Bottle sterilisation  
  Independent / Supervised / Assisted
Breastfeeding   
  Independent / Supervised / Assisted
Provisions for baby
  CUPS clinic appointment / Early childhood
clinic appointment
Blue Book
Discharge summary
Child at risk identification
Referral / No referral
Other agencies family referred to 
Source: Royal Hospital for Women, Randwick, NSW and the Langton Centre, Surry Hills, NSW.
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Australian categorisation of risk 
of drug use in pregnancy
Category A
Drugs which have been taken by a large number of 
pregnant women and women of childbearing age 
without any proven increase in the frequency of 
malformations or other direct or indirect harmful 
effects on the fetus having been observed.
Category C
Drugs which, owing to their pharmacological effects, 
have caused or may be suspected of causing, harmful 
effects on the human fetus or neonate without causing
malformations. These effects may be reversible.
Accompanying texts should be consulted for 
further details.
Category B1
Drugs which have been taken by only a limited number 
of pregnant women and women of childbearing age, 
without an increase in the frequency of malformation
or other direct or indirect harmful effects on the human 
fetus having been observed. Studies in animals have 
not shown evidence of an increased occurrence of 
fetal damage.
Category B2
Drugs which have been taken by only a limited number 
of pregnant women and women of childbearing age, 
without an increase in the frequency of malformation
or other direct or indirect harmful effects on the human 
fetus having been observed. Studies in animals are 
inadequate or may be lacking, but available data show 
no evidence of an increased occurrence of fetal damage.
Category B3
Drugs which have been taken by only a limited number 
of pregnant women and women of childbearing age, 
without an increase in the frequency of malformation
or other direct or indirect harmful effects on the 
human fetus having been observed. Studies in animals
have shown evidence of an increased occurrence of 
fetal damage, the significance of which is considered 
uncertain in humans.
Category D
Drugs which have caused, are suspected to have caused 
or may be expected to cause, an increased incidence
of human fetal malformations or irreversible damage. 
These drugs may also have adverse pharmacological
effects. Accompanying texts should be consulted for 
further details.
Category X
Drugs which have such a high risk of causing permanent 
damage to the fetus that they should not be used in
pregnancy or when there is a possibility of pregnancy.
Appendix 7: Categorisation of drug 
risks in pregnancy and breastfeeding 
Source: Therapeutic Goods Administration, Australian Drug Evaluation Committee, 1999, Prescribing medicines in 
pregnancy: an Australian categorization of risk of drug use in pregnancy 4th edition, Australian Department of Health 
and Ageing, Canberra, [inside front cover, no page number].
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Hale’s categorisation of 
breastmilk drug risks
L1 Safest
Drug which has been taken by a large number of 
breastfeeding mothers without any observed increase 
in adverse effects in the infant. Controlled studies in
breastfeeding women fail to demonstrate a risk to the 
infant and the possibility of harm to the breastfeeding
infant is remote or the product is not orally bioavailable
in an infant.
L2 Safer
Drug which has been studied in a limited number 
of breastfeeding women without an increase in
adverse effects in the infant. And/or the evidence
of a demonstrated risk which is likely to follow use of 
this medication in a breastfeeding woman is remote.
L3 Moderately Safe
There are no controlled studies in breastfeeding women; 
however, the risk of untoward effects to a breastfed 
infant is possible or controlled studies show only minimal
non-threatening adverse effects. Drugs should be given
only if the potential benefit justifies the potential risk to 
the infant.
L4 Possibly Hazardous
There is positive evidence of risk to a breastfed infant
or to breastmilk production by the benefits from use 
in breastfeeding mothers may be acceptable despite
the risk to the infant (eg if the drug is needed in a life-
threatening situation or for a serious disease for which
safer drugs cannot be used or are ineffective).
L5 Contraindicated
Studies in breastfeeding mothers have demonstrated 
that there is significant and documented risk to the 
infant based on human experience or it is a medication
that has a high risk of causing significant damage to 
an infant. The risk of using the drug in breastfeeding
women clearly outweighs any possible benefit from 
breastfeeding. The drug is contraindicated in women 
who are breastfeeding an infant.
Source: Hale Thomas W, 1992-2004, Medications and mothers’ milk, 11th edition, Pharmasoft Publishing LP, 
Amarillo, Texas, p18.
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NH&MRC GUIDELINE 11: Women 
who are pregnant or might soon 
become pregnant 
11.1 may consider not drinking at all.
11.2 most importantly, should never become intoxicated.
11.3 if they choose to drink, over a week, should have 
less than 7 standard drinks, AND, on any one day, 
no more than 2 standard drinks (spread over at least 
two hours).
11.4 should note that the risk is highest in the earlier
stages of pregnancy, including the time from conception
to the first missed period.
Rationale: Alcohol in a woman’s blood stream enters 
that of her unborn child, and this may affect the child
from conception onwards. It is difficult to identify exactly 
the lower levels of drinking at which alcohol may cause 
harm to the child and, for this reason, a woman may 
consider not drinking at all. 
Nevertheless, while more high quality research is
needed, the limited available evidence indicates that 
averaging less than one drink per day has no measurable 
impact on children’s physical and mental development. 
The evidence indicates that episodes of drinking above 
the guideline levels considerably increase the risk to the 
unborn child, including the risk of miscarriage, low birth
weight, cognitive defects and congenital abnormalities.
Heavy bouts of drinking maximise that risk.
The evidence base is discussed on page 77. See also 
pages 23 and 46. 
Comment: The most important consideration for 
women is to avoid a high blood alcohol level at any time
during the pregnancy. The first weeks after conception
are probably the most critical in relation to alcohol, and 
the woman is usually unaware of the pregnancy at this
stage. The guideline is therefore important not only for 
women who are pregnant, but for those who may soon 
become pregnant. 
The literature review undertaken for these guidelines
found no definite evidence that low-level drinking
causes harm to the unborn child. Other authorities
have, nevertheless, recommended no drinking during
pregnancy. Women may choose not to drink at all, out 
of caution, especially if relevant risk factors are present: 
for example, if the mother has health problems such as 
high blood pressure or poor nutrition. Good antenatal 
care and good diet, including folate and vitamin B 
supplements, and not smoking are also very important.
BREASTFEEDING—A Prudent 
Approach
Women who are breastfeeding are advised not to 
exceed the levels of drinking recommended during
pregnancy, and may consider not drinking at all.
Comment: Alcohol in the blood stream passes into
breast milk. There is little research evidence available
about the effect that this has on the baby, although 
practitioners report that, even at relatively low levels 
of drinking, it may reduce the amount of milk available
and cause irritability, poor feeding and sleep disturbance
in the infant. Given these concerns, a prudent approach 
is advised.
Appendix 8: Australian Alcohol 
Guidelines: pregnancy and breastfeeding
Source: This page is an extract from the Australian Alcohol Guidelines (NHMRC, 2001, p.16) available at
www.alcoholguidelines.gov.au/index.htm
PAGE 90  National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn
Appendix 9: Fagerström test for 
nicotine dependence
Fagerstrom Test for Nicotine 
Dependence*
1.  How soon after you wake up do you smoke your 
first cigarette?
After 60 minutes (0)
31-60 minutes (1)
6-30 minutes (2)
Within 5 minutes (3)
2.   Do you find it difficult to refrain from smoking
in places where it is forbidden?
No (0)
Yes (1)
3.  Which cigarette would you hate most to give up?
The first in the morning (1)
Any other (0)
4. How many cigarettes per day do you smoke?
10 or less (0)
11-20 (1)
21-30 (2)
31 or more (3)
5.   Do you smoke more frequently during the first hours 
after awakening than during the rest of the day?
No (0)
Yes (1)
6.   Do you smoke even if you are so ill that you are 
in bed most of the day?
No (0)
Yes (1)
Score
Your score was
Your level of dependence on nicotine is
0-2 Very low dependence 
3-4 Low dependence
5 Medium dependence
6-7 High dependence 
8-10 Very high dependence
Source: *Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nictoine Dependence: 
A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addictions 1991;86, p.1119-27
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Modified Finnegan’s scale
Infants of mothers known or suspected to be drug users 
who are showing signs of withdrawal should be scored 
every 4 hours. The scoring should be applied in
a consistent manner by personnel who are experienced
in dealing with such infants.
NOTE: Caution must be exercised before symptoms 
listed here are accepted as part of drug withdrawal.
For example, symptoms such as fever, tachypnoea 
or seizures could be due to sepsis, which should be 
excluded first with appropriate tests.
System Signs and symptoms Score 
CNS High-pitched cry 2
Continuous high-pitched
cry
3
Sleeps <1 hour after 
feeding
3
Sleeps <2 hours after 
feeding
2
Sleeps <3 hours after 
feeding
1
Mild tremors disturbed 1
Mod-severe tremors 
disturbed
2
Mild tremors undisturbed 3
Mod-severe tremors 
undisturbed
4
Increased muscle tone 2
Excoriation (specify area) 1
Myoclonic jerks 3
Generalised convulsions 5
System Signs and symptoms Score
Metabolic/
Vasomotor/
Respiratory
Fever (37.3-38.3 deg C) 1
Fever (>38.3 deg C) 2
Frequent yawning (>3-4 
times)
1
Nasal snuffiness 1
Sneezing (>3-4 times) 1
Nasal flaring 2
Respiratory rate > 60/min 1
Respiratory rate > 60/min
+ retractions
2
Gastrointestinal
disturbances
Excessive sucking 1
Poor feeding 2
Regurgitation 2
Projectile vomiting 3
Loose stools 2
Watery stools 3
Infants scoring 3 consecutive abstinence scores 
averaging more than 8 (eg 9-7-9) or ? 12 for 2 scores 
require treatment. The scoring interval should be 
4 hourly until the infant has been stabilised. Infants 
withdrawing from non-opiates frequently display similar
behaviours to those withdrawing from opiates.
For more information on Neonatal Abstinence Syndrome 
from the Royal Prince Alfred Hospital Department 
of Neonatal Medicine Protocol Book see 
www.cs.nsw.gov.au/rpa/neonatal/html/newprot/nas.htm. 
Appendix 10: Examples of neonatal 
abstinence syndrome scoring scales
Example 1: Royal Prince Alfred Hospital modified 
Finnegan’s Scale 
Source: Department of Neonatal Medicine Protocol Book, Royal Prince Alfred Hospital, Sydney, NSW
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Source: Women’s Alcohol and Drug Service (WADS), Royal Women’s Hospital, Melbourne Victoria.
Example 2: Women’s Alcohol and Drug Service 
NAS Scoring System
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Caring for your Baby with NAS
The brochure on the following pages is laid out for photocopying, collation and folding to create an A5 booklet.
Appendix 11: Example of parent 
information brochure on NAS
Source: Royal Prince Alfred Hospital, Sydney, New South Wales.
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Introduction: Severe neonatal abstinence syndrome 
(NAS) is a potentially life threatening medical illness.
Inpatient observation for 7 to 10 days after delivery
is recommended to avoid unsupervised withdrawal.
However, prolonged inpatient stay has significant
psycho-social and economic implications to both the 
infant’s family and the community. 
Aim: To evaluate appropriate duration of hospitalisation
sufficient to detect severe NAS prior to discharge.
Methods: We conducted a 2 year retrospective review
of all infants born to narcotic dependent women at the 
Royal Women’s Hospital in the time period between 
January 1998 and December 1999 (inclusive).
All infants were observed as inpatients utilising a 
modified Finnegan NAS scoring system until a minimum
of 7 days of age.
Severe NAS was defined as that requiring medical
therapy based on the recommendations of 
Finnegan et al.
Age in days when each infant first received medication
was recorded. 
Results: 203 infants exposed to regular maternal 
narcotic use during pregnancy were born during the 
study period.
40 (20 per cent) infants received postnatal oral morphine
therapy for symptoms of significant narcotic withdrawal.
Culmulative percentage of infants requiring 
medication for narcotic withdrawal
36 of the medicated infants were exposed to regular 
antenatal methadone, 4 were exposed to heroin only. 
38 infants (95 per cent) experienced peak symptoms of 
neonatal abstinence syndrome by 7 days of age. 
Conclusion: Discharge of infants born to narcotic-
dependent women prior to 7 days of life may result 
in a significant risk of these infants experiencing
symptoms of severe neonatal abstinence syndrome in an 
unsupervised environment.
Appendix 12: Duration of postnatal 
hospitalisation required to detect 
severe NAS
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Source: PN Henschke: Royal Women’s Hospital Chemical Dependency Unit, Carlton, Victoria.
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